

# VENTURE

# SPRIN-D



08 APRIL 2025  
ALTE MÜNZE BERLIN




AT VENTURE SPRIND,  
WE CONNECT  
BREAKTHROUGH  
STARTUPS BACKED  
BY SPRIND WITH  
VISIONARY INVESTORS,  
FOSTERING MEANINGFUL  
RELATIONSHIPS AND  
SPARKING INNOVATIVE  
COLLABORATION FOR  
ONE IMPACTFUL DAY.

A SPRUNGINNOVATION IS AN INNOVATION, THAT CHANGES OUR LIVES FOR THE BETTER IN THE LONG TERM.







IT CAN CREATE A  
COMPLETELY NEW MARKET,  
FUNDAMENTALLY CHANGE  
AN EXISTING MARKET TO  
CREATE A COMPLETELY NEW  
ECOSYSTEM, OR SOLVE A  
MASSIVE TECHNOLOGICAL,  
SOCIAL OR ENVIRONMENTAL  
PROBLEM.

SPRIND  
PROVIDES  
CUSTOM MADE  
FUNDING

SPRIND IS SEARCHING FOR  
WAYS TO OVERCOME THE  
SOCIAL, ENVIRONMENTAL  
AND ECONOMIC  
CHALLENGES OF OUR TIME.

SUPPORT OF SPRIND IS  
COMPREHENSIVE. WE  
FINANCE, COACH AND  
PROVIDE STRONG NETWORKS  
FROM FROM SCIENCE,  
BUSINESS AND POLITICS.

# SPRIND FUNDING INSTRUMENTS

## START-UP FUNDING

Through start-up funding, we support young companies that are not yet able to acquire sufficient funding from private sources. We use the start-up funding to build up the company, develop the technology and, if necessary, take the first steps towards commercialization. Funding is provided up to EUR 1 million.

## INVESTMENTS AND CONVERTIBLE LOANS

If the private venture capital market does not offer sufficient financing, we can invest directly in start-ups. New private investors must provide at least 30% of the financing round and, as lead investor, negotiate the terms on which SPRIND will then invest on an equal footing. We can use equity investments, convertible loans and any other instruments similar to equity investments.

## FUNDING FOR RESEARCH AND DEVELOPMENT

We support disruptive innovations during capital-intensive research and development stages and fund part of the development costs. The remaining costs are covered by private investments. Our funding is typically in the single-digit million euro range, although it can reach up to EUR 35 million in individual cases. SPRIND funding only has to be repaid in the event of success, in other words, if the start-up goes public, is sold or begins to distribute profits.

## SPRIND CHALLENGES

In the SPRIND challenges, teams with disruptive innovation potential currently receive between EUR 500,000 and three million per competition stage. Funding is provided as a pre-commercial contract for research and development.

## SPRIND FUNKEN

Every SPRIND Funke can be a small step towards great transformations. Like the challenges, the sparks are innovation competitions for pioneers with world-changing ideas – but even faster. Currently, teams receive up to EUR 350,000 per competition stage. As with the SPRIND challenges, funding is provided via pre-commercial contracts.

# CHALLENGES

THE GOAL:  
FINDING THE BEST  
SOLUTIONS TO TACKLE  
THE GRAND CHALLENGES  
OF OUR TIME.

THE APPROACH:  
SELECTING VISIONARY  
TEAMS WHO COMPETE ON  
RADICALLY NEW SOLUTIONS.  
ONLY THE BEST PERFORMING  
TEAMS ADVANCE TO THE  
NEXT STAGE AND RECEIVE  
ADDITIONAL FUNDING.



## SUCCESS FACTORS OF 10 CHALLENGES LAUNCHED:

MINIMAL BUREAUCRACY
14 days from application Deadline to funding approval for most Challenges.

FOCUS ON INVESTMENT READINESS
11 Spin-outs with strong research focus transitioning to commercial success.

WORLD-CLASS MENTORING
Experienced entrepreneurs, investors and industry leaders pressure-test each team's approach.



Want to use the Superconnectors software for your event? Scan the QR code to share your thoughts or get early access.

More at [superconnectors.io](https://superconnectors.io)

We're thrilled to partner with Superconnectors this year to support our portfolio companies by unlocking the social capital they need to grow and succeed. The concept is simple: level the playing field so every founder has access to life-changing connections.

We encourage you to make the most of this opportunity by using the web app during the event. Just scan the QR codes and help our founders make meaningful connections.

Superconnectors was born from a straightforward realization: while many startup events focus on raising money, few prioritize helping founders connect with the right people. The initiative first launched during Rotterdam's startup festival, Upstream, providing a space where meaningful connections could take center stage. The concept quickly gained momentum, evolving from a once-a-year side event into a series of over 20 events annually at the world's largest tech fairs, including CES, Slush, and Web Summit.

# CONTENT

## COMPUTING, ELECTRONICS AND OPTICS

GIXEL .....	54
INCIRT .....	64
LAST MILE SEMICONDUCTOR.....	66
MCD MODERN CAMERA DESIGNS.....	76
OPEN RADIO SYSTEMS.....	88
PIXEL PHOTONICS .....	94
QUANTUMDIAMONDS .....	98
SEMRON.....	108
TECHIFAB.....	116

## AI, ROBOTICS AND DRONES

AURYAL .....	22
BIOTX.AI.....	128
CONTINUUM INNOVATION.....	36
GETWING.....	52
MIRA VISION.....	80
MOLAB.AI .....	82
POLYBOT.....	92
RULEMAPPING .....	104
SECUBLOX .....	106
STANHOPE AI.....	114

## LIFE SCIENCES

CPTX.....	38
DEEPSPIN.....	40
IGUARD .....	60
MUCOSATEC.....	84
PRIAVOID .....	96
SNIPR BIOME.....	110
TILIBIT .....	118
TQ THERAPEUTICS.....	120
ULTRABRIGHT BIOTECH.....	124

### ENERGY TECH

BATENE.....	24
EMROD.....	44
FOCUSED ENERGY.....	50
MACROCARBON.....	70
MARVEL FUSION.....	72
ORE ENERGY.....	90
REVERION.....	102
SPARK E-FUELS.....	112
UNBOUND POTENTIAL.....	126
HALIOGEN POWER.....	58

### CLIMATE TECH

C3 BIOTECH.....	30
CARBON.ONE.....	34
CARBOCULTURE.....	32
ELSTAR DYNAMICS.....	42
ENADYNE.....	46
EVERYCARBON.....	48
GREENLYTE CARBON TECHNOLOGIES.....	56
ILLUTHERM.....	62
LIGNILABS.....	68
OLIMENT.....	86
TRANSMUTEX.....	122

### ADVANCED MATERIALS

AEVOLOOP.....	16
AMPHICO.....	18
AMPHISTAR.....	20
BIOPHELION.....	26
BIOTREASURE.....	28
MATERI-8 - POWERED BY 17CICADA.....	74
MIMOTYPE TECHNOLOGIES.....	78
RADICAL DOT.....	100

# AEVOLOOP

FULLY RECYCLABLE, MICROPLASTIC-FREE, MULTIPURPOSE PERFORMANCE PLASTICS AT COMPETITIVE PRICING.

---

## COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
14

WEBSITE  
aevoloop.com

LOCATION  
Leipzig, Germany

REVENUE  
30,000 EUR

## BUSINESS MODEL

aevoloop produces and licenses circular polymers and platform chemicals, partnering with industry to replace or enhance conventional plastics using existing infrastructure.

FUNDING DILUTIVE  
1,100,000 EUR

FUNDING COMMITTED  
2,000,000 EUR

FUNDING NON-DILUTIVE  
5,800,000 EUR

FUNDING NEEDED  
1,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SEED

## SUPERCONNECTORS



IDEAL CONNECTION  
PreSeed/Seed investors, Executives of  
chemical companies

CRITICAL ASK  
Access to Seed capital

## INNOVATION AND GROWTH

**TECHNOLOGY:** We transform plastic waste into fully recyclable plastics, thanks to a molecular design that enables genuine circularity.

**TRL 4:** We have customer-tested prototypes that demonstrate feasibility and performance.

**IP:** 4 pending applications, 1 notification of invention, 3 inventions in preparation

**STATUS:** Pilot validation is underway, with proven waste upcycling and new plastic production in kilogram-scale trials.

**NEXT MILESTONE:** Scaling to a ton scale pilot plant and validating cost efficiency.

**PROOF OF CONCEPT:** POC with Eppendorf; BASF and Evonik in preparation

**VISION:** Plastics are among humankind's greatest inventions. Aevoloop's vision is to eliminate their sustainability flaws, ensuring they become truly planet-proof.



Manuel Häußler  
Co-Founder



Philipp Kessler  
CEO



Carl Warkentin  
Co-Founder



Timo Witt  
CTO

[back to overview](#)

# AMPHICO

WE DISRUPT THE TEXTILE INDUSTRY  
THROUGH MATERIAL SCIENCE. LET'S  
DO BETTER, ONE SEASON AT A TIME.

---

## COMPANY DETAILS

FOUNDED  
2018

EMPLOYEES  
15

WEBSITE  
amphico.uk

LOCATION  
London, UK

REVENUE  
18,000 EUR

## BUSINESS MODEL

We have a B2B business model selling our textile to brands to be used in their garments and equipment. We have partnered with large textile distributor Toyoshima to achieve 5 commercialisation projects with other brands and have completed textile sampling with 68 other brands.

FUNDING DILUTIVE  
1,700,000 EUR

FUNDRAISING  
Q2-Q3/2025

FUNDING NON-DILUTIVE  
3,300,000 EUR

FUNDING NEEDED  
2,400,000 EUR

FUNDING ROUND  
PRE SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Textile supply chain stakeholders and investors as we deliver to early clients, 5 global brands and distributors plan to adopt our technology for their 2026/27 seasons which is worth €3.6M in future revenue. We have a great pipeline of interest around the world driven by changing regulations.

### CRITICAL ASK

Access to new venture capitalists interested in our upcoming Pre-Series A investment round. Our market access is strong, demonstrated by our partnership with Toyoshima, one of Asia's largest textile distributors.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Textile finishing is the last and most harmful stage where colours and functions are added, responsible for 20% of global water pollution and 1% of CO<sub>2</sub> emissions. Our technology reduces water usage by 90%, CO<sub>2</sub> by 50% and shortens production by 3 months for a 10% cost saving. All with no toxic PFAS.

**TRL:** Amphitex (PFAS free waterproof textile) and Amphicolor (waterless coloured textile): TRL 8: Technology demonstrated to have higher functionalities and colour qualities achievable using large scale manufacturing. Amphigill – TRL 4: Successful levels of gas exchange to support human life underwater demonstrated on a lab scale (1:50 scale).

**IP:** 1 patent awarded, 4 pending

**STATUS:** Our membrane and waterless colouring projects, Amphitex and Amphicolor, are currently undergoing manufacturing trials in Japan. The functionalise textile for breathing, Amphigill, has been validated on a reduced scale in laboratory experiments, which is being scaled up thanks to SPRIND.

**NEXT MILESTONE:** By Q3/2025, we will be fully mass-manufacturing PFAS-free textiles for the outdoors industry ready with maximum capacity of 1M sqm/year.

**PROOF OF CONCEPT:**

5 POCs - undisclosed clients at this time.

**VISION:** To revolutionise the textile industry by creating new functional fabrics while eliminating polluting and toxic chemicals from its manufacturing steps. SPRIND has pushed our material platform technology forward to deliver a gas exchange textile for breathing, Amphigill, with a vision to supporting human life underwater.



Jun Kamei  
CEO



Louise Anderson  
CTO

# AMPHISTAR

## MAKING BIOSURFACTANTS MAINSTREAM!

---

### COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
22

LOCATION  
Ghent, Belgium

WEBSITE  
amphistar.com

### BUSINESS MODEL

Developing, producing and commercializing biosurfactants B2B.

FUNDING DILUTIVE  
6,500,000 EUR

FUNDRAISING  
Q3/2025

FUNDING NON-DILUTIVE  
6,000,000 EUR

FUNDING NEEDED  
30,000,000 EUR

FUNDING ROUND  
SERIES A

### SUPERCONNECTORS



#### IDEAL CONNECTION

Experts in capital structure & debt financing

#### CRITICAL ASK

Access to capital. Access to capital structure expertise

## INNOVATION AND GROWTH

**TECHNOLOGY:** Flexible and scalable platform production technology that can convert nearly any type of biomass to a wide range of performant biosurfactants using biotech.

**TRL:** Portfolio spreads over TRL 4-7

**IP:** 9 patent applications - 3 granted

**STATUS:** Technology has reached pilot-scale implementation, allowing for real-world validation and performance assessment.

**NEXT MILESTONE:** Launch plant blueprints and permits secured.

**PROOF OF CONCEPT:** Hard surface cleaner launched to consumer together with Ecover & SC Johnson

**VISION:** Surfactants Reimagined:  
Pioneering a circular economy that cleans up our world, and our future!



Karolien Maes  
Co-Founder



Bernd Everaert  
CTO and Co-Founder



Sophie Roelants  
Co-Founder and COO

[back to overview](#)

# AURYAL

WE CREATE A HUMAN ALIGNED  
SUPERINTELLIGENCE THAT MAKES AI  
ACT IN CONJUNCTION WITH  
HUMANKIND.

---

## COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
7

WEBSITE  
auryal.com

LOCATION  
Berlin, Germany

REVENUE  
30,000 EUR

## BUSINESS MODEL

Our business model is to first create personalized agents for specific use-cases like education and personal mental training (B2B and B2C). Those lead to the development of a universal personalized agent that we sell to customers.

FUNDING COMMITTED  
1,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING NON-DILUTIVE  
1,200,000 EUR

FUNDING NEEDED  
2,000,000 EUR

FUNDING ROUND  
PRE-SEED

## SUPERCONNECTORS



IDEAL CONNECTION  
AI and deep-tech focused VCs

### CRITICAL ASK

Access to investors that can support us creating a European champion for human aligned superintelligence. Access to strategic partners esp. in the European AI ecosystem.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology interprets mental states, collected via non-invasive, consumer-ready EEG, to augment generative AI models with human cognition. We create the ultimate personalized agent, that can think and act like you.

**TRL6:** The principles are proven and initial artifacts are implemented. We will mature the technology to TRL 8 in 18 months.

**IP:** 2 patents in preparation.

**STATUS:** The technology is validated and now being implemented into an initial product offering in the upcoming 18 months.

**NEXT MILESTONE:** Development of our software „LINK“ and „CORE“ that form the basis of human aligned superintelligence by Q4/2025.

**PROOF OF CONCEPT:** PoC will be ready in Q4/2025 for the start of raising the pre-seed round.

**VISION:** AURYAL envisions a future where human potential is amplified by AI that respects and reflects individual values, fostering a harmonious coexistence where machine intelligence augments human intelligence to work in unity.



Thorsten O. Zander  
CEO



Dr. Simon Vogt  
Co-Founder

[back to overview](#)

# BATENE

MAKE ANY BATTERY BETTER: 20%  
HIGHER PERFORMANCE, 30% LOWER  
COST, 60% LESS METAL.

---

## COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
18

WEBSITE  
batenetec.com

LOCATION  
Wendlingen am Neckar, Ger-  
many

REVENUE  
235,000 EUR

## BUSINESS MODEL

Baten supplies 3D current collectors to battery manufacturers, cutting costs and boosting performance. We also license our technology to cell makers, suppliers, and equipment producers—enabling large-scale adoption and generating revenue through royalties.

FUNDING DILUTIVE  
10,000,000 EUR

FUNDING COMMITTED  
15,000,000 EUR

FUNDING NON-DILUTIVE  
233,000 EUR

FUNDING NEEDED  
24,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Manufacturers of high-performance battery cells, OEMs in automotive, aerospace, and electronics, and strategic investors with deep industry expertise.

### CRITICAL ASK

Access to capital, development partners, and industrial scaling opportunities.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our Batene fleece™ technology revolutionizes battery design with a 3D metal fiber current collector. It enables thick electrodes for higher energy density, faster charging, and lower costs while reducing material use, and enabling dry electrode production for greater efficiency and sustainability.

**TRL: 5** We have successfully tested our pouch cells and are now validating the technology in an industrial setting.

**IP:** 2 granted, 15 pending, 1 making

**STATUS:** Our technology is validated in the lab with coin and pouch cells and is now being tested in an industrial setting with partners. In parallel, we are scaling manufacturing with a 10 MWh pilot line, set to be built over the next 30 months.

**NEXT MILESTONE:** Industrial validation of Batene PouchCell 1436

**PROOF OF CONCEPT:** 4 POCs with Wyon, Cellforce, Mercedes & BMW

**VISION:** Our vision is a world where green energy is accessible anytime, everywhere—driven by high-performance, affordable batteries that power a sustainable future. Batene makes any battery better.



Thanh Nguyen  
Co-Founder



Martin Möller  
Co-Founder and CEO



Joachim P. Spatz  
Founder



Christian Boehm  
CEO

[back to overview](#)

# BIOPHELION

CREATION OF NON-FOSSIL BASED AND  
NON-SUGAR BASED PRODUCTS BY  
ROBUST AND AUTONOMOUS  
BIOPROCESSES.

---

## COMPANY DETAILS

FOUNDED  
2025

EMPLOYEES  
2 (+10 subcontractors)

LOCATION  
Jena, Germany

FUNDING NEEDED  
3,000,000 EUR

FUNDING COMMITTED  
3,500,000 EUR

FUNDING NON-DILUTIVE  
3,500,000 EUR

FUNDRAISING  
2026

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



IDEAL CONNECTION  
Distributor (e.g. Brenntag).

CRITICAL ASK  
Access to market for new molecules.



# INNOVATION AND GROWTH

TECHNOLOGY: Genetically modified microorganisms combined with innovative but robust and scalable bioprocess technology.

TRL: 4-6

IP: 1 awarded, 1 trade mark

STATUS: Foundation in progress (status March 13th)

NEXT MILESTONE: Q3/2025 - first product meets market requirements.

**VISION:** We develop technologies that make bioprocesses robust, autonomous and scalable, as these are the key elements to a relevant circular bioeconomy. To this end, we generate and implement ideas across the entire vertical, from new microorganisms to new bioreactor concepts, to generate platform chemicals from non-fossil and non-sugar-based feedstocks and turn them into customer-relevant products.



Lars Regestein  
CEO



Till Tiso

# BIOTREASURE

FERMENTING WASTE,  
CRAFTING VALUE.

---

## COMPANY DETAILS

FOUNDED  
to be founded in Q1 2026

EMPLOYEES  
8

LOCATION  
Munich, Germany

## BUSINESS MODEL

Our platform provides technology solutions that enhance operational efficiency and deliver products with lower carbon footprint and costs to businesses in high volume mass markets.

FUNDRAISING  
Q1 2026

FUNDING ROUND  
SEED

FUNDING NON-DILUTIVE  
3,500,000 EUR

## SUPERCONNECTORS



### IDEAL CONNECTION

Seed investors with biomanufacturing background

### CRITICAL ASK

We are seeking strategic partners and early investors to help scale our continuous biomanufacturing process for sustainable nylon production.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We utilize sustainable agricultural and forestry waste streams to produce polymers such as nylon. Using robust, non-conventional yeasts, we efficiently convert complex feedstocks. Our continuous bioreactor enables low-cost production, making bioproducts competitive in large commodity markets.

**BioMRL** (Biomanufacturing readiness level): 4

**IP:** 1 pending, 1 making

**STATUS:** Biotreasure is incubated at Insempra, a biotech company focused on biological ingredient production. With a prototype process developed, we are optimizing our continuous biomanufacturing to reduce costs, aiming to spin out and raise seed funding within the next year.

**NEXT MILESTONE:** Prototype sample production

**PROOF OF CONCEPT:** 5 advanced POCs with feedstock suppliers & 10 POCs with potential customers

**VISION:** BioTreasure's mission is to revolutionize biomanufacturing by transforming waste into high-volume products with minimal impact. Our continuous system reduces costs and resource use, tackling waste management and sustainability for a greener future.



Luisa Gronenberg



Ed Van Der Ent



Johannes Sonnenschein



Ruchita Chawla

[back to overview](#)

# C3 BIOTECH

REIMAGINE BIOMANUFACTURING COST AND PRODUCTION BARRIERS, TO ENTER THE COMMODITY CHEMICAL MARKET.

---

## COMPANY DETAILS

FOUNDED  
2015

EMPLOYEES  
20

LOCATION  
Manchester, United Kingdom

WEBSITE  
c3biotech.com

## BUSINESS MODEL

C3 is centered around the sale and licensing of intellectual property (IP), specialized expertise, and detailed blueprints, enabling clients to build sustainable manufacturing operations with optimized performance and long-term profitability.

FUNDING NEEDED  
25,000,000 EUR

FUNDING COMMITTED  
5,940,000 EUR

FUNDING NON-DILUTIVE  
21,200,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Brand developer, Licensing clients, R&D investor

### CRITICAL ASK

Access to market and brand exposure. Ideal introduction to a brand ambassador, business communicator and global event organiser.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Integrated in-house engineered bacteria, infrastructure and process chemistry, dramatically reducing CAPEX and OPEX through non-sterile production. Offering a sustainable, and revenue generating, alternative to traditional biomanufacturing methods.

**TRL 5:** Plastic non-sterile fermentation at 100 L scale moving to 800 L within the next month.

**IP:** 2 awarded , 18 pending

**STATUS:** Revenue Streams: Licensing, fees for partner solutions, joint ventures, and sales / **Milestones:** 2026: Launch of Acrylics pilot plant / 2027: Demonstrator plant operational and licensing/ 2028: Expansion to manufacturing plants and other commodity chemicals

**NEXT MILESTONE:** Q2 2025- Patent pending fermenter technology test and scaling

**VISION:** To reimagine biomanufacturing by leveraging non-sterile platforms to drive mass production of high-volume commodity chemicals, breaking down cost barriers and unlocking scalable, revenue-generating opportunities.



Nigel Scrutton  
Co-Founder and CSO



Daniele Parisi  
Senior Scientist



Timothy Daffern  
Shareholder



Ryan McBerney  
Senior Scientist

[back to overview](#)

# CARBOCULTURE

## MITIGATING CLIMATE CHANGE WITH A SCALABLE BIOCHAR PRODUCTION TECHNOLOGY.

---

### COMPANY DETAILS

FOUNDED  
2016

EMPLOYEES  
35

LOCATION  
Helsinki, Finland

WEBSITE  
carboculture.com

### BUSINESS MODEL

We will build, own, and operate reactor systems that produce biochar. Our business model is to sell the biochar, carbon storage, and energy produced to high-tech agriculture, green steel, and concrete and cement producers who are in need of a sustainable pathway.

FUNDING DILUTIVE  
26,000,000 EUR

FUNDING COMMITTED  
20,000,000 EUR

FUNDING NON-DILUTIVE  
6,000,000 EUR

FUNDING NEEDED  
50,000,000 EUR

FUNDING ROUND  
SERIES B

FUNDRAISING  
Q4/2025

### SUPERCONNECTORS



IDEAL CONNECTION  
Investors

#### CRITICAL ASK

We need access to capital to fund our first-of-a-kind facility. The FOAK is a critical step

towards proving our technology, to ultimately enable us to access more traditional project financing sources and drive this critical climate technology to an industrial scale.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We own and operate an industrial-scale biochar technology and act as the project developer. The company produces biochar and energy for both green steel and for permanent carbon removal with high-tech agriculture, as well as replacing cement with our condensed products.

**TRL:** Current TRL level 6

**IP:** 2 awarded, 5 pending, 1 making

**STATUS:** The technology is validated through several stages of R&D facilities, with the next step being the commercial FOAK to be built in 2026

**NEXT MILESTONE:** Commercial FOAK facility financial close Q4 2025

**PROOF OF CONCEPT:** Successful product testing conducted with several large scale customers

**VISION:** We are working to avoid the worst impacts of climate change by removing CO<sub>2</sub> from the atmosphere. Plants draw down CO<sub>2</sub>, and our reactor converts it to biochar, permanently storing the carbon. We will scale Biochar Carbon Removal by developing valuable carbon-based products.



Henrietta Moon  
Co-Founder and CEO



Kristian Husman  
Head of Finance and Admin

# CARBON.ONE

## MAKING GREEN METHANOL COST COMPETITIVE.

---

### COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
33

LOCATION  
Berlin, Germany

WEBSITE  
carbon.one

### BUSINESS MODEL

The first chemical process we commercialize is our breakthrough homogeneous catalysis for the production of methanol. We lower the production cost of green methanol, which helps defossilize container shipping, aviation and carbon-based chemical production.

FUNDING DILUTIVE  
28,600,000 EUR

FUNDING COMMITTED  
10,000,000 EUR

FUNDING NON-DILUTIVE  
12,000,000 EUR

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SERIES A

### SUPERCONNECTORS



#### IDEAL CONNECTION

Industry experts from the chemical space with expertise in the field of catalyst development, plant (reactor) design and operations or along the methanol value chain.

#### CRITICAL ASK

Access to capital, both equity and project based financing.





## INNOVATION AND GROWTH

**TECHNOLOGY:** We own the value chain all the way from molecule to industrial production. First we identify novel catalysts via quantum-mechanical computer simulation. Then we optimize them using in-house laboratories. Finally, we design and build industrial chemical plants.

TRL 6

IP: 2 patents awarded, 1 pending, 2 in the making

**STATUS:** We operate a fully continuous, fully autonomous pilot plant in the Leuna chemical park. We will take the FID on our first commercial demonstration plant ( $\approx 20$  tons/day capacity) in 2025.

**NEXT MILESTONE:** 20t/d demonstration plant

**PROOF OF CONCEPT:** Pilot plant in the chemical park in Leuna, more info see <https://www.leuna100.de/>

**VISION:** We disrupt the chemical industry by reinventing century old chemical catalysis processes.



Christian Vollmann  
Co-Founder and CEO



Marek Checinski  
Co-Founder and CTO



Mathias Mostertz  
CTO



Haik Mehmkke  
CFO

[back to overview](#)

# CONTINUUM INNOVATION

## JOIN THE ROBOT REVOLUTION.

---

### COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
4

LOCATION  
Berlin, Germany

WEBSITE  
[continuum-innovation.de](https://continuum-innovation.de)

### BUSINESS MODEL

Sale (and integration) of our robotic arm to B2B customers. Future exploration of the B2C market

FUNDING DILUTIVE  
0,00 EUR

FUNDING COMMITTED  
400,000 EUR

FUNDING NON-DILUTIVE  
400,000 EUR

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q3 - Q4 / 2025

FUNDING ROUND  
SEED

### SUPERCONNECTORS



#### IDEAL CONNECTION

Experienced robot integrating company, blue chip size at best

#### CRITICAL ASK

Although we have a lot of experience in R&D, we still need more expertise for development towards market maturity. We are looking for an expert who has already accompanied a complex hardware product from development to market readiness and can advise us on these topics or network with us.

## INNOVATION AND GROWTH

**TECHNOLOGY:** The robotic arm, which moves like an elephant's trunk using continuous mechanics, can operate in confined spaces and moves much more flexibly and safely than conventional robots, thereby increasing efficiency and safety in automated processes and everyday environments.

TRL 5

IP: 1 patent pending

**STATUS:** lab tests of our prototype, pilot customer tests planned this year with to customers

**NEXT MILESTONE:** Testing prototype at pilot customer

**PROOF OF CONCEPT:** PoC done with Liebherr, testing planned with Bosch, Siemens and Wacker Chemie

**VISION:** We are developing a universal, scalable soft cobot that fundamentally changes the areas of application of robotic arms and the interaction with them. The continuous mechanics and sensor technology enables safe and accessible automation of manual labour in all areas of life and work.



Kilian Reiss  
CEO

# CPTX

WE ARE PIONEERING A NEW CLASS OF COMPOSITE PROGRAMMABLE THERAPEUTICS (CPTX), LEVERAGING DNA NANOFABRICATION TO TRANSFORM MEDICINE WITH UNPARALLELED PRECISION, PROGRAMMABILITY, AND EFFICACY. OUR TECHNOLOGY UNLOCKS NEW POSSIBILITIES IN TARGETED DRUG DELIVERY, GENETIC MEDICINE, AND NEXT-GENERATION ANTIVIRALS.

---

## COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
40

LOCATION  
Munich, Germany

WEBSITE  
[cptx.bio](http://cptx.bio)

## BUSINESS MODEL

CPTx's business approach integrates strategic collaborations with pharmaceutical companies alongside the in-house development of innovative therapeutics. Currently, CPTx's efforts are centered on advancing treatments in the areas of antivirals and genetic medicine.

FUNDING DILUTIVE  
21,000,000 EUR

FUNDING NON-DILUTIVE  
5,000,000 EUR

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Pharmaceutical and biotech companies (next-generation therapeutics), partners with expertise in drug development, clinical translation, and commercialization

### CRITICAL ASK

We are looking for strategic partnerships, investors, and talent to scale our composite programmable therapeutics platform. We seek connections to pharmaceutical and biotech companies.

## INNOVATION AND GROWTH

TECHNOLOGY: DNA nanofabrication

IP: More than 10 patents awarded and pending

STATUS: CPTx has assembled a team of more than 30 scientists and built state-of-the-art infrastructure dedicated to developing next-generation DNA-based therapeutics.

PROOF OF CONCEPT: Various in vitro and in vivo studies have presented compelling evidence showing the effectiveness and potential applications of CPTx's DNA nanofabrication platform.

VISION: CPTx is pioneering a new class of therapeutics, built on DNA nanofabrication, to revolutionize medicine. CPTx's technology enables nanometer-level precision, integrating multiple therapeutic functions for safer and more effective treatments.



Hendrik Dietz  
CEO



Christian Sigl  
CTO

# DEEPSPIN

WORLD'S FIRST FLATBED MRI.  
10X LOWER COST. FULLY OPEN.  
FULLY MOBILE.

---

## COMPANY DETAILS

FOUNDED  
2020

EMPLOYEES  
20

WEBSITE  
[deepspin.io](https://deepspin.io)

LOCATION  
Berlin, Germany

REVENUE  
Pre-Revenue

## BUSINESS MODEL

DeepSpin's business model is based on a combination of scanner purchase, per scan fee and subscription fee. Their super low production cost allow software-like margins while additionally benefiting from a much stronger customer lock-in. Their strategic value chain position at the point of data acquisition allows them to increase their value capture over time by offering AI-powered diagnosis support software.

FUNDING DILUTIVE  
8,000,000 EUR

FUNDING NON-DILUTIVE  
5,220,000 EUR

## SUPERCONNECTORS



### IDEAL CONNECTION

Chairs of Radiology/Urology at (University) hospitals; C-level at private radiology or urology chains; C-level at focal ablation therapy companies - ideally US-based.

### CRITICAL ASK

Connections to (US) imaging industry leaders & C-levels at hospital, imaging, urology, preventive care chains; plus connections to health policy makers in Germany / EU.

## INNOVATION AND GROWTH

**TECHNOLOGY:** DeepSpin has developed a proprietary AI-powered approach for enabling MRI in inhomogeneous magnetic fields. Simply put: We can use simpler and lower cost hardware and compensate this through our software.

**TRL:** 7 Technology fully proven through phantom scans. Clinical scans upcoming this year.

**IP:** 5 patent families consisting of 19 (pending) patents.

**STATUS:** DeepSpin has proven its groundbreaking technology through imaging of phantoms with a full scale scanner and is on track to receive FDA-clearance for their first product within the next year.

**NEXT MILESTONE:** Q4/2025 - FDA submission

**PROOF OF CONCEPT:** LOIs from >20 globally leading hospitals and clinics. \$30 M pipeline of revenue conditional on FDA clearance.

**VISION:** Making lifesaving medical imaging through MRI universally accessible.



Clemens Tepel  
Co-Founder and CEO



Pedro Freire Silva  
Co-Founder and CTO

# ELSTAR DYNAMICS

## ACHIEVING NET ZERO.

---

### COMPANY DETAILS

FOUNDED  
2019

EMPLOYEES  
20

LOCATION  
Eindhoven, The Netherlands

WEBSITE  
elstar-dynamics.com

### BUSINESS MODEL

Our business model is to outsource manufacturing to existing high capacity manufacturers, whilst then supplying the technology directly to existing industries around the world, for integration into the end applications.

FUNDING DILUTIVE  
12,000,000 EUR

FUNDING COMMITTED  
15,000,000 EUR

FUNDING NON-DILUTIVE  
1,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING ROUND  
SERIES B

### SUPERCONNECTORS



IDEAL CONNECTION  
Industry partners and regulators

CRITICAL ASK  
Access to capital, markets & regulators



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology is the only glazing solution that can bring significant energy savings at an affordable cost, whilst being the **ONLY** technology with the manufacturing capacity to meet demand.

**TRL 7:** We are commercially sampling the technology from qualified MP partner facilities.

**IP:** We have 129 patents in; 24 families; with, 63 granted, and; 29 pending, with a further 33 published, and; 4 allowed.

**STATUS:** Our technology has been independently validated by some of the world's leading organisations. We are now planning to scale the technology over the next 12 - 24 months, in order to commercially sample customers.

**NEXT MILESTONE:** Launch of a Commercial Smart Window

**PROOF OF CONCEPT:** PoCs with Profine, Aisin, Skylux, AGC, NSG and preparations for the same with Velux, Permasteelisa and Foster + Partners.

**VISION:** To crack the code of achieving Net Zero across all living conditions.



Anthony Slack  
CEO



Jos Hof  
CFO



Romaric Massard  
CTO

# EMROD

POWER, ANYWHERE. OUR VALUE PROPOSITION IS TO ENHANCE THE FLEXIBILITY OF POWER TRANSMISSION THROUGH COMMERCIALISING POWER BEAMING TECHNOLOGY. REDUCE THE BURDEN ON BATTERIES AND ACCELERATE THE TRANSITION FROM FOSSIL FUELS.

---

## COMPANY DETAILS

FOUNDED  
2019

EMPLOYEES  
8

WEBSITE  
[emrod.energy](http://emrod.energy)

LOCATION  
Berlin, Germany

REVENUE  
250,000 EUR

## BUSINESS MODEL

Our business model is to sell our systems to end users and OEMs, as well as earn a transmission-as-a-service fee for operating and maintaining the technology.

FUNDING DILUTIVE  
3,800,000 EUR

FUNDING COMMITTED  
5,300,000 EUR

FUNDING NON-DILUTIVE  
1,300,000 EUR

FUNDING NEEDED  
1,800,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

Hardware-focused climatech investors coming in at SEED and Series A stage.

### CRITICAL ASK

Access to capital and talent network in Berlin.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We develop and commercialize safe, long-range wireless power transmission. Our system converts electricity into electromagnetic energy, transmits it via antennas, and reconverts it back. With 95% beam efficiency, it scales from kW to GW over kilometers. Our first prototype powers cargo drones dynamically.

TRL 5: indoor prototype demonstrated

IP: 5 pending

**STATUS:** We have demonstrated our end-to-end prototype for Airbus and the European Space Agency (ESA), validating the system and our approach. We're currently developing prototypes for our flagship customer, a cargo drone operator in Dubai.

**NEXT MILESTONE:** Q3/2025 - Technical validation of first use case: demonstrating power beaming to a drone during take-off and landing.  
**PROOF OF CONCEPT:** POC with Airbus and the European Space Agency

**VISION:** Our vision is a world unconstrained by the movement of energy.



Greg Kushnir  
Founder and CEO



Ray Simpkin  
CSO



Andrew Wallace  
Commercial Director

# ENADYNE

## INNOVATIVE GREEN CHEMICALS BASED ON NON-THERMAL PLASMA.

---

### COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
30

WEBSITE  
[enaDyne.com](http://enaDyne.com)

LOCATION  
Leipzig, Germany

REVENUE  
1,000,000 EUR

### BUSINESS MODEL

Technology Sale // Technology-as-a-Service // Licensing / We have a primary focus selling our container-based plasma catalysis solution or providing it in a technology-as-a-service setting. We also offer plasma-based emission abatement solution for highly climate toxic emissions such as CF<sub>4</sub>.

FUNDING DILUTIVE  
8,300,000 EUR

FUNDING ROUND  
SERIES A

FUNDING NEEDED  
18,000,000 EUR

FUNDRAISING  
END OF 2026

### SUPERCONNECTORS



#### IDEAL CONNECTION

Leaders in the areas of chemistry, catalysis as well as operators of industrial and biogenic CO<sub>2</sub> and CH<sub>4</sub> point sources that are looking to decarbonize.

#### CRITICAL ASK

Access to pilot partners/lead customers

## INNOVATION AND GROWTH

**TECHNOLOGY:** enaDyne develops non-thermal plasma catalysis reactors that enable the efficient electrification of chemistry. The technology allows the synthesis of high-value chemicals from CO<sub>2</sub> as well as the abatement of century chemicals with much lower energy consumption compared to conventional technologies.

**TRL 4-5:** Currently scaling the technology towards industrial application.

**IP:** 2 awarded, 1 pending

**STATUS:** The technology is validated in the lab and is currently being scaled for industrial applications during the next 24 months.

**NEXT MILESTONE:** Prototype for CF<sub>4</sub> abatement by end of 2025 / Pilot container solution for CO<sub>2</sub> valorization by mid 2026

**PROOF OF CONCEPT:** Three POCs with industrial and academic partners.

**VISION:** Revolutionize how chemistry is done with highly efficient non-thermal plasma catalysis.



Philipp Hahn  
Co-Founder

# EVERYCARBON

EVERYCARBON IS THE PLATFORM SOLUTION FOR VALORIZING THE ABUNDANCE OF MIXED-MATERIAL WASTE BIOMASS FOR BIOMANUFACTURING.

---

## COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
6

LOCATION  
Stuttgart, Germany

WEBSITE  
[everycarbon.bio](http://everycarbon.bio)

## BUSINESS MODEL

We engage in B2B-retail of boutique chemical products from non-fossil resources, as well as service- and licensing products to retrofit existing infrastructure.

FUNDING COMMITTED  
3,500,000 EUR

FUNDING NON-DILUTIVE  
3,500,000 EUR

FUNDING ROUND  
PRE-SEED

FUNDING NEEDED  
2,200,000 EUR

FUNDRAISING  
Q3/2025

## SUPERCONNECTORS



### IDEAL CONNECTION

Large scale waste biogas producers: Veolia, Remondis, Suez, PreZero.

### CRITICAL ASK

We need an introduction to a large waste and wastewater management company willing to retrofit an existing waste management site with a demo size EveryCarbon plant.

## INNOVATION AND GROWTH

**TECHNOLOGY:** EveryCarbon delivers sustainable bio-based chemicals via multi-stage fermentation, ensuring a consistent supply independent of global supply chains. Our platform uniquely integrates diverse and mixed waste biomasses to deliver high-quality, carbon-negative chemicals.

**TRL 4:** 90 days continuous operation of our multi-stage fermentation process converting mixed industrial food-waste to our bulk chemical.

**IP:** 2 pending

**STATUS:** The technology has been proven at lab scale and is currently scaled for validation and process optimization to pilot-scale co-located at a waste-water treatment plant.

**NEXT MILESTONE:** Q2 2025 - Completion of our mini-plant, which is co-located at a waste-water treatment plant.

**VISION:** In an EveryCarbon world, waste management and the production of high-performance materials are exactly the same thing.



Sebastian Beblawy  
Co-Founder and CEO



Leonie Rominger  
Bioprocess engineer



Apolonio I. Huerta  
Business Strategy Manager

[back to overview](#)

# FOCUSED ENERGY

## LASER FUSION WILL UNLOCK OUR NEXT GREAT CHAPTER OF GROWTH.

---

### COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
75

WEBSITE  
[focused-energy.co](https://focused-energy.co)

LOCATION  
Darmstadt / San Francisco

REVENUE  
800,000 USD

### BUSINESS MODEL

Our business model is an IP licensing and fuel sale model. We design laser fusion reactors, sell those designs to power operators, earn laser IP license fees and sell the target fuel for reactors. It is a capital-light deep tech business model.

FUNDING DILUTIVE  
40,000,000 USD

FUNDRAISING  
Q2/2025 (we are live now)

FUNDING NON-DILUTIVE  
828,000 EUR

FUNDING NEEDED  
150,000,000 USD

### SUPERCONNECTORS



IDEAL CONNECTION  
deep-tech investors/German industrial family  
offices

CRITICAL ASK  
Europe - based deep tech investor  
introductions





## INNOVATION AND GROWTH

**TECHNOLOGY:** Laser Fusion achieved fusion ignition in 2021, net energy gain in 2022 and continues to make repeated strides forward. We believe that Laser Fusion and its proven results are the best path forward to a commercial fusion power plant. And we have the team that did it.

**TRL** for the coare laser technology is 4; several other componets need more development path.

**IP:** We hold IP in laser amplification and cooling, as well as targetry design. Our on-going R&D efforts will yield many more patents and trade secrets.

**STATUS:** Laser fusion is the **ONLY** fusion approach operating on a post-gain path

the engineering solutions. And we are the only laser fusion company with a developer customer and an industry consortium ready to start building.

**NEXT MILESTONE:** Q2/2025- Target Lab Darmstadt goes live.

**PROOF OF CONCEPT:** The ley proof-of concept comes from the Lawrence Livermore National Laboratory where laser fusion achieved scientific energy gain. We are peer reviewed and part of the BMBF Fusion 2040 Program as a multiple awardee as well as the US DoE PPP selecting us as 1 of 8 fusion companies worthy of their support. We are the only fusion company with a power developer customer.

**VISION:** Powering the next step-function change for civilization



Scott Mercer  
Founder and CEO



Pravesh Patel  
CTO



Christopher Wendel  
CFO

[back to overview](#)

# GETWING

REVOLUTIONIZING AVIATION WITH  
BLENDED WING BODY DESIGN TO  
REDUCE DRAG AND ENHANCE  
EFFICIENCY.

---

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
5

WEBSITE  
getwing.com

LOCATION  
Hamburg, Germany

REVENUE  
150,000 EUR

## BUSINESS MODEL

Our business model is to become the leading producer of blended-wing-body aircraft, delivering superior efficiency, extended range, and increased cargo and passenger capacity for airlines and logistics providers.

FUNDING COMMITTED  
1,000,000 EUR

FUNDRAISING  
Q1/2026

FUNDING NON-DILUTIVE  
220,000 EUR

FUNDING NEEDED  
12,000,000 EUR

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

Aerospace and cargo industry leaders, logistics operators, strategic investors, and government agencies focused on sustainable aviation, firefighting, and humanitarian logistics.

### CRITICAL ASK

Seeking strategic investors and industry partners for funding and market access. Key needs: capital for prototype development, certification, and scaling, plus partnerships for operational deployment in logistics.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology prioritizes drag reduction for maximum efficiency, enabling higher speeds, extended range, and increased cabin volume. The self-stable blended-wing-body (BWB) design revolutionizes aircraft performance, offering a more sustainable and versatile future for aviation.

TRL 6: building first manned prototype

IP: 1 Design Patent awarded

**STATUS:** Our technology is validated through subscale prototypes in test flights. We are now scaling towards a full-size manned demonstrator, to be flown within the next 6 months.

**NEXT MILESTONE:** By 2028 - „Flight of the full scale demonstrator for our 10-seater aircraft.“

**PROOF OF CONCEPT:** We have one PoC with „wings for aid“ for unmanned cargo in humanitarian missions.

**VISION:** Our vision is a future where everyone can fly anywhere, sustainably and affordably.



Filip Piskorzynski  
Co-Founder and CEO



Bernhard Mattlener  
COO

[back to overview](#)

# GIXEL

REVOLUTIONIZING AR DISPLAYS WITH  
HIGH-EFFICIENCY, RETINA-QUALITY  
VISUALS FOR AI-POWERED GLASSES.

---

## COMPANY DETAILS

LOCATION  
Karlsruhe, Germany

WEBSITE  
gixel.de

EMPLOYEES  
13

## BUSINESS MODEL

We build the display tech that will define the next era of computing. Our innovation powers AI and spatial computing devices, enabling mass-market adoption of immersive wearables.

FUNDRAISING  
Q3/2025

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



**IDEAL CONNECTION**  
Investors and industry leaders shaping the future of AI-driven AR wearables.

**CRITICAL ASK**  
High-impact investors and manufacturing partners to accelerate AR's leap into everyday life.

## INNOVATION AND GROWTH

**TECHNOLOGY:** AR displays have long been held back—resulting in poor visuals and limited battery life. Gixel’s breakthrough displaytech powers AI & spatial computing—bringing retina-quality visuals, wide FOV, and all-day efficiency to wearable devices.

**TRL:** 5 Validated in lab and relevant environments, proving next-gen AR display performance. Next step: industry pilots and hardware integration.

**IP:** Strong patent portfolio with multiple granted patents, securing key AR display innovations.

**STATUS:** We’re backed by an all-star team of advisors and angels – Oculus founders Palmer Luckey, Brendan Iribe, Flixbus founders, and AR visionary Ted Schilowitz, among others. We’re at the prototype stage, with strong interest from top-tier OEMs, and we’re getting ready for preproduction.

**NEXT MILESTONE:** Q3/2025 - Showcasing next-gen AR display prototype—proving the leap toward mass-market AI glasses.

**PROOF OF CONCEPT:** SVP-level engagement with consumer electronics giants—strong buy-in, PoCs to follow.

**VISION:** AI and AR converge to create an insanely great new reality—one that reshapes how we live, work, and play.



Ding Luo  
Co-Founder



Felix Nienstaedt  
Co-Founder



Miro Taphanel  
CEO

# GREENLYTE CARBON TECHNOLOGIES

## FUELING CIRCULAR CARBON.

---

### COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
55

LOCATION  
Essen, Germany

WEBSITE  
[greenlyte.tech](https://greenlyte.tech)

### BUSINESS MODEL

Sell hydrocarbons (e-methanol, SAF, etc.); Sell DAC plants

FUNDING DILUTIVE  
22,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING NON-DILUTIVE  
20,000,000 EUR

FUNDING NEEDED  
25,000,000 EUR

FUNDING ROUND  
SERIES A

### SUPERCONNECTORS



IDEAL CONNECTION  
Open to networking

CRITICAL ASK  
Access to capital/ potential off-takers of  
hydrocarbons/ etc.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We are developing the world's most efficient DAC process. We capture CO<sub>2</sub> in a liquid absorbent and desorb it while co-producing hydrogen. We will defossilize various hard-to-abate industries globally by providing green feedstock at competitive prices and thus disrupting oil & gas industry.

**TRL:** 5 DAC technology validated in relevant environment – several upscaled prototypes for absorption and desorption built up under real weather conditions. By Q2 2025, TRL 6 – Tech demonstrated by fully integrated and robust operation of absorption and desorption unit outside

**IP:** 1 awarded, 6 pending, 3 making

**STATUS:** The technology is validated in the lab and at several test stands (first 100t DAC plant in Germany). Currently developing an upscaled plant at ZBT in Duisburg coupling DAC with green SNG production. In 2026 building of FOAK plant (DAC-2-E-Methanol) at Chempark Marl (Evonik).

**NEXT MILESTONE:** Q3/2025 First CCU plant (DAC-2-SNG) commissioned

**PROOF OF CONCEPT:** >10 prototypes at different scales; commercial traction (off-take agreements, LOIs, etc.)

**VISION:** Our vision is to transform atmospheric CO<sub>2</sub> into valuable resources, creating a sustainable, circular carbon economy that restores ecological balance and decisively tackles climate change.



Florian Hildebrand  
Co-Founder and CEO



Niklas Friederichsen  
Co-Founder

# HALIOGEN POWER

HALIOGEN POWER ENABLES THE WORLD'S DECARBONISATION BY PROVIDING A RESILIENT, SUSTAINABLE AND AFFORDABLE LONG DURATION BATTERY TO MAKE RENEWABLE ENERGY ACCESSIBLE ANYWHERE, ANYTIME, AND FOR ANYONE.

---

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
13

LOCATION  
Manchester, UK

WEBSITE  
[haliogen-power.com](http://haliogen-power.com)

## BUSINESS MODEL

Our business model is to sell long duration batteries (hardware) to industrial, commercial, utilities, infrastructure and urban areas; with a view to expand into energy-as-a-service.

FUNDING NEEDED  
8,500,000 EUR

FUNDRAISING  
Q2/2025

FUNDING NON-DILUTIVE  
4,500,000 EUR

FUNDING ROUND  
SEED

## SUPERCONNECTORS



IDEAL CONNECTION  
Investors, Industrial & Commercial Partners

CRITICAL ASK  
Access to capital; partners for pilots in H2/2025 and 2026



## INNOVATION AND GROWTH

**TECHNOLOGY:** We have reimagined the traditional redox flow battery by developing a cutting-edge membraneless alternative. Our batteries remove the need for costly, non-recyclable membranes and instead rely on abundant raw materials, resulting in more sustainable, operationally efficient, affordable, and non-flammable long-term energy storage solution.

TRL 5

IP: 1 awarded

**STATUS:** The technology has been validated in a lab environment with a prototype launched in Q2/2025. We are working on scaling the 1kW system to a pilot ready system for commercial testing in H2/2025.

**NEXT MILESTONE:** Q2/2025 - 1kW / 10kWh Battery Pilot System

**VISION:** We believe that HalioGen Power batteries will become the backbone of the world's energy infrastructure. We want to become the catalyst and enabler for the clean energy transition.



Daniel Palme  
Co-Founder and CEO



Dr. Lewis Le Fevre  
Co-Founder and CTO



Andinet Ejigu  
Co-Founder and CSO



Thanasis Stergiou  
Co-Founder and CCO

[back to overview](#)

# IGUARD

IGUARD WILL REVOLUTIONIZE RESPIRATORY MEDICINE WITH PRECISION RNA INHALATION THERAPY TO SAVE PATIENTS THAT CANNOT BE CURED TODAY.

---

## COMPANY DETAILS

### FOUNDED

To be founded in 2025

### LOCATION

Hanover, Germany

### EMPLOYEES

4

## BUSINESS MODEL

iGUARD will develop, produce and sell RNAi inhalation drugs. We provide our platform and delivery technology for fee-for-service, co-development, and sub-licensing.

FUNDING NEEDED  
4,800,000 EUR

FUNDRAISING  
Q3/2025

FUNDING NON-DILUTIVE  
4,750,000 EUR

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

Experienced BD/Finance or VC investor for biotech and RNA technology

### CRITICAL ASK

We are looking for a business developer or CFO with international track record for biotech or RNA technology, ideally with experiences in Big Pharma M&A.

## INNOVATION AND GROWTH

**TECHNOLOGY:** The iGUARD technology provides a fast-track drug development pipeline and integrated delivery tool for RNAi inhalation therapeutics.

**TRL 4:** in vivo PoC, initial preclinical toxicology, initial Pharmacokinetics

**IP:** 2 pending, 1 making

**STATUS:** We are 4 founders looking for an investor for the late preclinical program. Coming up: Preclinical testing and clinical Phase I study plan

**NEXT MILESTONE:** By Q3 2025: Company founded. By Q4 2026: Preclinical testing accomplished, clinical in human trial application sent.

**PROOF OF CONCEPT:** In vivo efficacy PoC

**VISION:** We will revolutionize respiratory medicine with precision RNA therapy for inhalation to save patients that cannot be cured today.



Adrian Schwarzer



Armin Braun



Philippe Vollmer

# ILLUTHERM

WE DECARBONIZE INDUSTRIAL HEAT  
AT REDUCED ENERGY COST.

---

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
9

WEBSITE  
[illutherm.com](https://illutherm.com)

LOCATION  
Darmstadt, Germany

REVENUE  
> 100,000 EUR

## BUSINESS MODEL

We develop and distribute LED-furnaces to materials manufacturers.

FUNDING DILUTIVE  
1,700,000 EUR

FUNDING COMMITTED  
>2,000,000 EUR

FUNDING NON-DILUTIVE  
300,000 EUR

FUNDING NEEDED  
15,000,000 EUR

FUNDRAISING  
2026

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



IDEAL CONNECTION  
Visionary LED Engineer

### CRITICAL ASK

We need smart (electrical) Engineers today  
and access to capital in 2026.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our LED furnaces heat materials directly, rather than first heating the surrounding air. We use blue light—technology that wasn't available just five years ago—boosting efficiency by a factor of 10.

**TRL:** 5-6

**IP:** 5 filed, 2 in the making

**STATUS:** We have found an infinitely scalable assembly approach and validated it at 3.6 kW (world brightest LED) at customer sites. We are assembling a 15 kW version and will expand to a 50 kW pilot by early 2026.

**NEXT MILESTONE:** Pilot plant operational by Q2/2026

**PROOF OF CONCEPT:** 10 PoCs with steel, lime, glas and ceramic

**VISION:** We replace the ancient concept of a furnace. With intense blue light from LEDs, heat steel, cement and ceramics to beyond 1400 °C with mere seconds. With our disruptive LED-furnace we will replace coal and gas fired furnace across different industries saving up to 5% of global CO<sub>2</sub> emissions.



Dr. Lukas Porz  
CEO and Co-Founder



Michael Scherer  
CTO and Co-Founder



Milto Vlachos  
COO and Co-Founder

# INCIRT

## ENABLING NEXT GENERATION WIRELESS COMMUNICATION AND DIGITAL RADARS.

---

### COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
15

WEBSITE  
incirt.de

LOCATION  
Aachen, Germany

REVENUE  
250,000 EUR

### BUSINESS MODEL

We sell breakthrough data converter technology as semiconductor IP or physical chips / chiplets.

FUNDING DILUTIVE  
700,000 EUR

FUNDING COMMITTED  
3,500,000 EUR

FUNDING NON-DILUTIVE  
CA. 5,000,000 EUR

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SEED

### SUPERCONNECTORS



#### IDEAL CONNECTION

System architects in leading positions at WiFi and radar companies

#### CRITICAL ASK

Looking for investors + top-notch CTO that can help us build commercial product in short time frame

## INNOVATION AND GROWTH

TECHNOLOGY: Data converter technology that is 100x faster than state of the art, 10x more energy efficient than state of the art, and that can be implemented in semiconductor technology readily available in Europe.

TRL 6: chips validated in relevant environment

IP: 1 awarded, 1 pending

STATUS: Our latest prototypes outperform state of the art by 6x. Within next 24 months we plan to arrive at commercially ready products.

NEXT MILESTONE: By Q4/25 independently testable chip to be sent to potential customers

PROOF OF CONCEPT: 2 PoCs with Nokia and Sivers

**VISION:** Ultra high-speed wireless connectivity everywhere, ultra low-cost AI services, usable quantum computers, unprecedented radars. All related technology completely sourced in Europe.



Sebastian Waters  
Co-Founder

# LAST MILE SEMICONDUCTOR

## NON-CELLULAR 5G/6G SOC'S FOR SMART EDGE AI APPLICATIONS.

---

### COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
25

WEBSITE  
lm-semi.com

LOCATION  
Dresden, Germany

REVENUE  
2,000,000 EUR

### BUSINESS MODEL

We are selling Wireless Semiconductor worldwide.

FUNDING DILUTIVE  
500,000 EUR

FUNDING COMMITTED  
5,500,000 EUR

FUNDING NON-DILUTIVE  
5,000,000 EUR

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q1/2026

FUNDING ROUND  
SERIES A

### SUPERCONNECTORS



IDEAL CONNECTION  
Deep Tech and Semiconductor Investors.

CRITICAL ASK  
Money for Semiconductor.



## INNOVATION AND GROWTH

TECHNOLOGY: Our SoC is the answer for professional IoT Infrastructure of tomorrow.

STATUS: We have our first chipset available in Q3/2025.

TRL 6

NEXT MILESTONE: Q3/2025 Tapeout First Silicon.

IP: 4 awarded, 5 pending, 6 making

VISION: Democratizing 5G with NR+.



Christopf Gulich  
CEO

[back to overview](#)

# LIGNILABS

LIGNILABS' BIO-BASED  
ENCAPSULATION ENHANCES STABILITY,  
CONTROL, AND SUSTAINABILITY WITH  
UNMATCHED FLEXIBILITY.

---

## COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
5

LOCATION  
Mainz, Germany

WEBSITE  
[lignilabs.de](https://lignilabs.de)

## BUSINESS MODEL

LigniLabs develops custom bio-based encapsulation solutions and supplies them in limited quantities. For larger-scale production, it offers a licensing model for partners. Additionally, LigniLabs is developing its own innovative products. This flexible approach ensures a scalable, sustainable value chain across industries.

FUNDING COMMITTED  
1,500,000 EUR

FUNDING NON-DILUTIVE  
1,120,000 EUR

FUNDING ROUND  
PRE-SEED

FUNDING NEEDED  
2,500,00 EUR

FUNDRAISING  
Q2/2025

## SUPERCONNECTORS



### IDEAL CONNECTION

The ideal connection would be with companies and partners in the chemical industry, to initiate new projects and identify further areas of application for the LigniCAPS technology.

### CRITICAL ASK

We are looking for sufficient capital to create the conditions for value creation. Furthermore, all regulatory issues for the agricultural sector are to be clarified in the near future.

## INNOVATION AND GROWTH

**TECHNOLOGY:** LigniLabs developed a pioneering biobased micro- and nanoencapsulation technology using lignin, enabling the encapsulation of virtually any active ingredient in any matrix with exceptional versatility. Its scalable and cost-efficient production process, combined with customizable release mechanisms, makes it ideal for various applications.

**TRL 7-8:** The demonstration of the platform technology was successful and the first products are being developed in various application areas.

**IP:** 1 awarded, 2 pending

**STATUS:** The technology is validated in the lab and is currently being scaled for industrial applications during the next 18 months. LigniLabs is in initial negotiations regarding commercial projects with potential customers from industry.

**NEXT MILESTONE:** Closing of the financing round and initiation of the first commercial project.

**PROOF OF CONCEPT:** 2 POCs with Max-Planck and Covestro

**VISION:** LigniLabs is revolutionizing material science with bio-based micro- and nanoencapsulation, enabling precise, controlled release and replacing synthetic alternatives. Our scalable technology is driving a new era of smart, sustainable solutions across industries like agriculture and plastics.



Alexander Throm  
Co-Founder and CEO



Justin Grabow  
Co-Founder and CTO

# MACROCARBON

## DE-FOSSILIZE HUMANITY'S CARBON SUPPLY CHAIN.

---

### COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
6

LOCATION  
Las Palmas des Gran Canaria

WEBSITE  
[macrocarbon.world/en](https://macrocarbon.world/en)

### BUSINESS MODEL

Our business model is to develop integrated seaweed farms with processing facilities to provide a full integrated value chain to local communities.

FUNDING DILUTIVE  
2,400,000 EUR

FUNDING ROUND  
SEED

FUNDING NON-DILUTIVE  
2,200,000 EUR

FUNDING NEEDED  
2,000,000 EUR

FUNDRAISING  
Q2/2025

### SUPERCONNECTORS



#### IDEAL CONNECTION

Investors in deep tech interested in vertical integration.

#### CRITICAL ASK

Access to capital to finish de-risking our technology.

## INNOVATION AND GROWTH

TECHNOLOGY: Floating seaweed aqua farms with an integrated processing supply chain to produce biofuels (naphtha and SAFs)

TRL 5: Aquafarms - We had demonstrated the farm design and seaweed growth at small scale in the relevant environment. Processing - TRL 6-7: Initial pilot plant has been demonstrated.

IP: Developing two applications for farm design.

STATUS: Our technology is validated at the small pilot scale and will be developed through to TRL 7 in the next 18 months.

NEXT MILESTONE: By Q3/2025 - Deployment and testing of 40,000m2 aquafarm.

PROOF OF CONCEPT: PoC with Borealis, Airbus, Iberia, and Repsol.

**VISION:** Our vision is to use the world's most sustainable biological feedstock to make the chemical and aviation industries carbon negative.



Jason Cole  
CEO



Mar Fernández-Méndez  
CEO

# MARVEL FUSION

SAFE, CLEAN, ABUNDANT FUSION  
ENERGY FOR HUMANITY.

---

## COMPANY DETAILS

FOUNDED  
2019

EMPLOYEES  
70

LOCATION  
Munich, Germany

WEBSITE  
[marvelfusion.com](http://marvelfusion.com)

## BUSINESS MODEL

After the construction of an initial prototype power plant, Marvel Fusion will build fusion power plants (300-800Mwe) in cooperation with partners to meet the world's soaring need for cost-competitive green energy.

FUNDING DILUTIVE  
220,000,000 EUR

FUNDING COMMITTED  
435,000,000 EUR

FUNDING NON-DILUTIVE  
215,000,000 EUR

FUNDING ROUND  
SERIES B+

## SUPERCONNECTORS



### IDEAL CONNECTION

Deep-tech industry leaders, industrial partners in areas like energy generation, powerplant development, laser technology

### CRITICAL ASK

Access to investors; supply-chain partners, political contacts to discuss public-private partnerships

## INNOVATION AND GROWTH

**TECHNOLOGY:** Developing a scalable, cost-competitive laser-based fusion power plant based on – 20x more efficient laser systems – 30x more compact design – 100x higher energy coupling with nanostructured fuel targets.

TRL 3-4

**IP:** Relevant IP for critical areas in target and laser development have been submitted / patents have been granted

**STATUS:** The laser system is designed, and first parts have already been assembled. The technology will be first demonstrated in the laser facility currently under construction in Colorado. In parallel, the

company works with Siemens Energy on a preliminary power plant design and other industrial partners on the manufacturing and scaling of its fusion targets.

**NEXT MILESTONE:** By 2027 - Full proof-of-technology at laser facility in Colorado.

**PROOF OF CONCEPT:** Powerplant development project with Siemens Energy Laser development with renowned partners in the US and Lithuania Target development with world-leading chemistry companies and nanofabrication experts Go-to-market strategy with partners in energy intensive industries (datacentres, steel and chemistry industries).

**VISION:** Marvel Fusion will empower the world with clean and affordable baseload energy to drive economic growth and social equity.



Moritz von der Linden  
CEO



Heike Freund  
COO



Dr. Nicolas Burkardt  
CFO

# MATERI-8 - POWERED BY 17CICADA

WE MAKE THE UNRECYCLABLE  
RECYCLABLE.

---

## COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
8

LOCATION  
Nottingham (UK), Munich (GER)

WEBSITE  
17cicada.com

## BUSINESS MODEL

Our business model is to sell commodity base chemicals to (specialty) chemistry companies at half the cost and half the global warming impact of our competitors.

FUNDING DILUTIVE  
119,000 GBP

FUNDING ROUND  
SEED

FUNDING NON-DILUTIVE  
1,800,000 GBP

FUNDING NEEDED  
2,500,000 EUR

FUNDRAISING  
Q3/2025

## SUPERCONNECTORS



### IDEAL CONNECTION

Director of operations or regulatory officer of  
Renewi, PreZero, Remondis, etc.

### CRITICAL ASK

An introduction to communities or waste  
industry representatives who really struggle  
to find a solution for their plastics or textiles  
waste stream



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology is a novel biological platform that uses proprietary microorganisms to transform unrecyclable waste valuable commodity chemicals.

**TRL 4:** Demonstrated successful waste conversion in a 100L laboratory reactor

**IP:** 1 awarded, 1 making

**STATUS:** The technology is currently being tested in the lab at larger scale, in parallel

to the evaluation of economic viability. This will be finished by end of Q2/2025, with the target of scaling for commercial applications 24 months later.

**NEXT MILESTONE:** Q2/2025 - scaling to 100L and Q4/2025 1000L – demo scale

**PROOF OF CONCEPT:** 1 large recycling company (NL), 2 large corporates with industrial waste (UK, GER) and 3 specialty chemistry companies (UK, IT)

**VISION:** Our vision is to enable a circular bioeconomy in which circular materials are made from unrecyclable waste for a less polluted earth.



Patricia Parlevliet  
CEO



Samantha Bryan  
CTO



Peter Knight  
COO



Andrew Rogan  
CCO

[back to overview](#)

# MCD MODERN CAMERA DESIGNS

REVOLUTIONIZING HIGH VOLUME OPTICAL MANUFACTURING: SIGNIFICANT COST & ENERGY REDUCTION.

---

## COMPANY DETAILS

FOUNDED  
2019

EMPLOYEES  
10

WEBSITE  
m-c-d.eu

LOCATION  
Jena, Germany

REVENUE  
130,000 EUR

## BUSINESS MODEL

Enabling innovations that require high-quality optics Design, manufacture, and sell customized polymer imaging optics for any quantity (from prototypes to billions of units) of any resolution.

FUNDING COMMITTED  
10,000,000 EUR

FUNDING NON-DILUTIVE  
2,400,000 EUR

FUNDING ROUND  
SERIES A

FUNDING NEEDED  
20,000,000 EUR

FUNDRAISING  
Q2/2025

## SUPERCONNECTORS



IDEAL CONNECTION  
active in consumer optics / smartphones

CRITICAL ASK  
access to capital, access to consumer market (smartphones)

## INNOVATION AND GROWTH

**TECHNOLOGY:** Scalable platform technology for replicated low-cost, high-quality polymer optics combining the advantages of injection molding (freedom of shapes) and wafer-level-optics (parallelization and high temperature compliant materials) with cost and performance advantages

**TLR 5-6:** upcoming demo system for medium resolution (entrance level smartphones)

**IP:** no patents

**STATUS:** Prototypes for medical (endoscopy) and automotive (cameras) realized – Paid PoC projects for low res. objective lenses for medical and consumer applications

**NEXT MILESTONE:** demo of high resolution objective lens

**PROOF OF CONCEPT:** POC with smartphone OEM

**VISION:** Replacing Market Leader (Largan, \$2bn rev.) Polymer lenses with same quality at: – Significantly reduced production steps (-90%) – Significantly reduced energy consumption (-90%) – Significant cost reduction



Frank Wippermann  
Co-Founder and CEO



Jacques Duparre  
Co-Founder

# MIMOTYPE TECHNOLOGIES

WE TAP INTO NATURE'S OPEN SOURCE  
CODE TO CREATE CHEAPER, BETTER  
AND CLEANER MATERIALS FOR BIO-IN-  
SPIRED TECHNOLOGIES.

---

## COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
4

WEBSITE  
[mimotype.org](http://mimotype.org)

LOCATION  
Berlin, Germany

REVENUE  
300,000 EUR

## BUSINESS MODEL

We produce Green Fluorescent Protein variants at scale and deliver them to entirely new material systems with our customers.

FUNDING DILUTIVE  
1,000,000 EUR

FUNDING COMMITTED  
2,000,000 EUR

FUNDING NON-DILUTIVE  
1,000,000 EUR

FUNDING NEEDED  
3,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
PRE-SEED

## SUPERCONNECTORS



IDEAL CONNECTION  
Deep Bionanotech Investor

CRITICAL ASK  
Pre-seed round

## INNOVATION AND GROWTH

**TECHNOLOGY:** A major focus is the transformation of fluorescent proteins (FP) from molecular probes into nanoscale factories for active materials in optoelectronic devices and biosensors.

**TRL 6:** Designing and producing next-gen fluorescent proteins for advanced materials

**IP:** 1 awarded

**STATUS:** Validated with customers, enabling completely new bio-optical material systems.

**NEXT MILESTONE:** Q1/2026: First designed fluorescent protein with advanced functionality for nanotech application.

**PROOF OF CONCEPT:** Modern Synthesis, Fibrothelium, UCL Photonics Innovation Group

**VISION:** We will interface biology with technology using light.



Claudio Flores  
Co-Founder and CEO



Danilo Flores  
Co-Founder and Managing Director

# MIRA VISION

WE TRANSFER DECADES OF  
PATHOLOGY WISDOM INTO AI —  
REPLICATING EXPERT MINDS FOR  
FASTER, SMARTER DIAGNOSTICS.

---

## COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
14

LOCATION  
Göppingen & Erlangen

WEBSITE  
mira.vision

## BUSINESS MODEL

Our business model is evolving. We explore pay-per-use diagnostics, platform access, and offering our own lab services to bypass regulatory barriers — all designed for scalability, low cost, and global access to expert-level medical AI.

FUNDING DILUTIVE  
750.000,00€

FUNDRAISING  
Q3/2025

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

Key decision-makers and experts in the pharma industry, lab & diagnostics sector (human & veterinary), as well as oncology and pathology specialists. Additionally, we seek strategic partnerships with leading hospitals, research institutions, and AI-driven healthcare innovators.

### CRITICAL ASK

We seek an Expert Advisor for the pharma market and lab/diagnostics sector (human & veterinary), as well as a medical expert. Additionally, we need access to the pharmaceutical industry, excluding Boehringer Ingelheim and Merck, and oncology and pathology generalists.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our proprietary synthetic data engine powers diagnostic AI with unmatched efficiency, diversity and privacy — enabling accurate, scalable pathology without real patient data and with minimal computational resources.

**TRL 4:** Successful demonstration of usage of synthetic data in medical application for Malaria detection and muscle pathology outperforming SOTA models. Technology validated in relevant environments, with synthetic data pipeline and key AI components successfully tested against real-world pathology use cases.

**IP:** 2 pending, 1 making

**STATUS:** Parts of the technology are in validation. We're preparing PoVs and real-world cases to showcase performance — aiming to outperform Microsoft's Virchow 2 in scalability, efficiency, and accuracy within the next 12 months.

**NEXT MILESTONE:** Q2/2026 Surpassing Microsoft's Virchow2

**PROOF OF CONCEPT:** 5 PoC  
Musclepathology, PD-L1, Malaria, Breast Cancer, Cervical Cancer

**VISION:** Our vision is to provide a unique technology that makes medical diagnostics sustainable and accessible to everyone.



Lukas Mürdter  
CEO



Leonid Mill  
CTO and Co-Founder

# MOLAB.AI

BETTER SMALL MOLECULE DRUGS.  
FASTER.

---

## COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
6

WEBSITE  
[www.molab.ai](http://www.molab.ai)

LOCATION  
Munich, Germany

REVENUE  
250,000 EUR ARR

## BUSINESS MODEL

We are following a dual track of A) discovering small molecule drugs for de-risked blockbuster targets ourselves and outlicensing them to big pharma partners and B) forming R&D partnerships in which we discover small molecule drugs for targets chosen by our big pharma partners in exchange for upfront cash, milestones and royalties.

FUNDING DILUTIVE  
1,800,000 EUR

FUNDRAISING  
Q3/2025

FUNDING NON-DILUTIVE  
300,000 EUR

FUNDING NEEDED  
10,000,000 - 20,000,000 EUR

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

Investors at the intersection of Biotech and  
Tech / TechBio

### CRITICAL ASK

Access to capital.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our platform is a next-generation drug design engine integrating computation, AI, data and translational assays for holistic in silico multiparameter optimization of differentiated drugs.

**TRL:** 7 parts of our platform are in production at top 20 big pharma, the remainder is used and further advanced in our in-house discovery programs

**STATUS:** Our technology is fully proven in several discovery programs and our AI engine has been successfully

commercialized at a top 20 pharma - our lead discovery program (STAT6) is in early lead optimization, aiming for in vivo POC by Q4 2025.

**NEXT MILESTONE:** Q2/2025 Additional platform POC through identification of Lead Compound for STAT6 program.

**PROOF OF CONCEPT:** Successful commercialization of AI ADMET Engine at Merck KGaA, two further POCs from paid collaboration with German Biotech and own discovery program.

**VISION:** We're giving patients radically faster access to superior small molecules drugs and enable a step-change in drug discovery economics by de-risking and accelerating programs.



Simon Tatomir  
Co-Founder

# MUCOSATEC

THE MUCUS ENGINEERING COMPANY  
– PROTECTING VULNERABLE PEOPLE  
FROM VIRUS INFECTIONS.

---

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
7

LOCATION  
Schiffweiler (Saarland) and  
Berlin

WEBSITE  
[mucosatec.eu](https://mucosatec.eu)

## BUSINESS MODEL

MucosaTec's goal is to reach clinical Phase I through funding. Subsequently, we aim to establish a strategic partnership to successfully navigate clinical Phases II and III. With MucosaTec's platform technology, the path is set for developing new drug candidates targeting novel pathogens.

FUNDING NEEDED  
4,000,000 EUR

FUNDRAISING  
Q2+3/2025

FUNDING NON-DILUTIVE  
2,500,000 EUR

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

VC with experience in pharma and/or strategic partner.

### CRITICAL ASK

Contact, advice and mediation in the areas of market entry, regulation and technology.

## INNOVATION AND GROWTH

**TECHNOLOGY:** A natural boost for the body's first line of defense – the human mucus. MucosaTec traps viruses within the mucus using a bifunctional construct, reducing viral load and alleviating symptoms. The platform technology can be tailored to address the current threat of choice.

**TRL:** 4 Efficacy and safety studies in vitro completed, gram-scale manufacturing of quantities of bulk product and proposed formulated product, currently preparing for GLP toxicity studies.

**IP:** 1 awarded, 1 making

**STATUS:** MucosaTec's lead candidate is currently at the end of the preclinical phase entering the regulatory toxicity studies. New drug candidates targeting Herpes and *Pseudomonas aeruginosa* are in the early stages of development. We are currently seeking for Series A funding (EUR 4M) for the next 2 years.

**NEXT MILESTONE:** Entering toxicity studies with our lead candidate.

**PROOF OF CONCEPT:** In vitro data indicate an efficient drug candidate with long-term stability.

**VISION:** Viruses bypass mucus, spreading uncontrollably and causing severe infections. Mucosal infections kill millions yearly. We envision a future in which vulnerable populations are treated and protected against threats by enhancing the natural mucus barrier independent of their immune history.



Anja Himmelstein  
Co-Founder



Marius Hittinger  
CEO

# OLIMENT

CHEAPER AND BETTER CEMENT –  
HIGHLY SCALABLE AND ZERO-CARBON.

---

## COMPANY DETAILS

FOUNDED  
2021

EMPLOYEES  
26

LOCATION  
Espenhain (Close to Leipzig),  
Germany

WEBSITE  
oliment.com

## BUSINESS MODEL

License Oliment to global cement industry as drop-in solution while continuously improve IP and product portfolio

FUNDING DILUTIVE  
8,000,000 EUR

FUNDING NON-DILUTIVE  
1,000,000 EUR

FUNDRAISING  
2025

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Off-takers (globally), experts in cement or concrete

### CRITICAL ASK

We are looking for contacts (globally) in construction, concrete, real estate and quarry operation. Bonus would be small or regional cement players worldwide.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Oliment is based on olivine ( $\text{Mg}_2\text{SiO}_4$  - abundantly available) and is produced in a kiln at  $800^\circ\text{C}$  which is about half the temperature of conventional cement ( $1,450^\circ\text{C}$ ) requiring only 40% of thermal energy, allowing flexible electricity load. Oliment is a drop-in solution for the global cement industry

**TRL:** 6-7 Pilot plant with 1 t/d in production, currently scaling to 100t/d

**IP:** 10 patents

**STATUS:** Current production capacity in demo plant already 1 t/d. Strong demand from cement and construction industry, as well as concrete end users (still in stealth mode)

**NEXT MILESTONE:** FOAK (First-of-a-kind) Oliment plant to proof scalability

**PROOF OF CONCEPT:** several PoCs with large construction players

**VISION:** Replace 25% of climate-damaging cement with  $\text{CO}_2$ -free Oliment globally by 2045 leading to 500 Mtons of  $\text{CO}_2$  reduction per year



Alexander Butt



Frank Bellmann

# OPEN RADIO SYSTEMS

## OPEN SOURCE RADIOS FOR 5G AND BEYOND.

---

### COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
9

LOCATION  
Darmstadt, Germany

WEBSITE  
[openradiosystems.com](https://openradiosystems.com)

### BUSINESS MODEL

We sell our software base stations to companies that install and operate private 5G networks. We customize our base station software for industrial networks, from the service layer down to the antenna. We also open our ecosystem to other developers to create new services at the edge.

FUNDING DILUTIVE  
25,000 EUR

FUNDING COMMITTED  
1,000,000 EUR

FUNDING NON-DILUTIVE  
998,825 EUR

FUNDING NEEDED  
2,000,000 EUR

FUNDRAISING  
Q1/2026

FUNDING ROUND  
SEED

### SUPERCONNECTORS



#### IDEAL CONNECTION

Investors in deeptech, telecommunications and open source solutions; Mobile network operators; Federal regulators for spectrum and security

#### CRITICAL ASK

Access to capital, access to key customers

## INNOVATION AND GROWTH

TECHNOLOGY: High-performance Software Defined Radio (SDR) with exclusive synchronization technology based on particle accelerators

- 5G Software Base Station with higher scalability, more bandwidth, and newer 5G standards than the competition
- 100% open source policy to prevent backdoors, lock in, and IP poisoning — builds trust and makes mobile infrastructure a public good

TRL: 7 5G software base station tested indoors, 1st outdoor test conducted

IP: 2 making

STATUS: Our prototype has been demonstrated in its operational environment and is currently being prepared for certification and field testing in Q3/2025.

NEXT MILESTONE: Q3/2025: Field test of our 5G base station with customer

PROOF OF CONCEPT: 2 PoCs

**VISION:** We are replacing proprietary radio hardware with open source software. Our 5G base station is an app running at full scale in a data center. Its code is open for anyone to review, and 6G is just an update away.



Christian Freund  
CEO



Stefan Valentin  
CTO



Raphael Hasler

# ORE ENERGY

DECARBONIZE THE ELECTRICITY GRID.

## COMPANY DETAILS

FOUNDED 2023	EMPLOYEES 40
LOCATION Amsterdam, Niederlande	WEBSITE oreenergy.com

## BUSINESS MODEL

Our business model involves designing, manufacturing, and deploying low-cost, multi-day iron-air energy storage systems, partnering with project developers, utilities and renewable energy developers to offer grid-scale storage solutions enhancing renewable integration and energy grid reliability.

FUNDING DILUTIVE 3,000,000 EUR	FUNDING COMMITTED 8,000,000 EUR	FUNDING NON-DILUTIVE 11,000,000 EUR
FUNDING NEEDED 40,000,000 EUR	FUNDRAISING Q4/2025	FUNDING ROUND SERIES A

## SUPERCONNECTORS



**IDEAL CONNECTION**  
Industry leaders in energy field, deep tech financiers

**CRITICAL ASK**  
Access to capital, access to market, access to talent



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology is a breakthrough iron-air battery system utilizing reversible oxidation of iron, enabling multi-day energy storage at ultra-low cost with abundant, safe, and scalable materials, dramatically reshaping renewable grid reliability.

**TRL 6-7:** we will soon deploy the first iron-air batteries connected to the electricity grid

**IP:** 4 pending, 2 making

**STATUS:** The technology is validated in the lab and operational environment.

**NEXT MILESTONE:** Q3/2026 'FOAK commissioning'

**PROOF OF CONCEPT:** Proof of Concept was developed in house. It will be tested together with one of the largest utility companies in Europe

**VISION:** Decimating the cost of electricity to make electricity grid carbon free

### TEAM

Aytac Yilmac  
Co-Founder and CEO

Rutil Özdemir  
COO

# POLYBOT

## UNLOCKING A SUSTAINABLE FUTURE FOR HUMANITY'S FOOD PRODUCTION.

---

### COMPANY DETAILS

LOCATION  
Tübingen, Germany

WEBSITE  
[polybot.eu](http://polybot.eu)

EMPLOYEES  
5

### BUSINESS MODEL

We will provide our robotic platform to growers through a subscription based business model.

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING NON-DILUTIVE  
1,500,000 EUR

FUNDING ROUND  
SEED

### SUPERCONNECTORS



#### IDEAL CONNECTION

CEO of large greenhouse vegetable growers in the Netherlands; venture funding decision makers fitting our long-term sustainability vision.

#### CRITICAL ASK

Strategic partnership with companies for green house solutions and large growers.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We develop AI algorithms to train off-the-shelf robots for new tasks using a single pipeline. Leveraging the latest advances in behavioral cloning and robot learning, this pipeline adapts to new activities quickly through demonstrations, without the need for rule development or manual adjustments.

**TRL 4:** Autonomous harvesting of truss tomatoes in the lab.

**IP:** Powerful ML pipeline.

**STATUS:** We have validated tomato harvesting in the lab and we will transfer the technology to greenhouses together with our partner growers within 2025.

**NEXT MILESTONE:** Q3/2025 - Harvesting feasibility (Validierungsauftrag)

**PROOF OF CONCEPT:** On farm mechanical weeding PoC.

**VISION:** Our vision is sustainable food production through small dexterous robots that master a wide range of precision tasks like harvesting and weeding in record time.




Wieland Brendel



Martin Kiefel



Sebastian Blaes



Maike Kaufman

# PIXEL PHOTONICS

ENABLING REVOLUTIONARY  
BREAKTHROUGHS FOR HUMANITY BY  
SOLVING THE BOTTLENECK OF NIR  
PHOTON DETECTION.

---

## COMPANY DETAILS

FOUNDED  
2020

EMPLOYEES  
35

WEBSITE  
pixelphotonics.com

LOCATION  
Münster, Germany

REVENUE  
2,500,000 EUR

## BUSINESS MODEL

Our business model is to sell our detection systems to OEMs and end-customers for their photon detection needs across markets and establish Pixel Photonics as the go-to player.

FUNDING DILUTIVE  
1,450,000 EUR

FUNDING COMMITTED  
253,000 EUR

FUNDING NON-DILUTIVE  
5,200,000 EUR

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SEED

## SUPERCONNECTORS



**IDEAL CONNECTION**  
DeepTech Investors with an interest /  
trackrecord in Photonics.

**CRITICAL ASK**  
Investors interested in joining our current  
funding round, Strategic Partnerships.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our chip-integrated photon detectors are a fundamentally new approach for NIR-detection, that dramatically reduce the cost-per-system and enable our customers to integrate next-gen detection performance into their systems.

**TRL 7:** Standalone Systems, **TRL 3-5:** Embedded / Co-Integrated

**IP:** 5 Granted, 2 Pending, 5 In-the-making

**STATUS:** Multiple standalone plug-and-play systems have been sold to customers.

**NEXT MILESTONE:** Converting to foundry-based production by Q4/25

**PROOF OF CONCEPT:** 2 PoCs with Quantum Computing Player, 1 PoC with a strong Research Consortium

**VISION:** Our vision is that the biggest breakthroughs in the future will be driven by advancements in photonic technology.



Nicolai Walter  
Co-Founder and CEO



Wladick Hartmann  
Co-Founder and CTO



Christoph Seidenstücker  
Co-Founder and CFO

# PRIAVOID

DEVELOPING EFFECTIVE TREATMENTS  
AGAINST SOME OF THE MOST DEVAS-  
TATING NEUROLOGICAL DISORDERS.

---

## COMPANY DETAILS

FOUNDED  
2017

EMPLOYEES  
25

LOCATION  
Düsseldorf, Germany

WEBSITE  
priavoid.com

## BUSINESS MODEL

Our business model is to translate our technological concept to various indications and partner with Pharma for later stage developments.

FUNDING DILUTIVE  
77,000,000 EUR

FUNDING NON-DILUTIVE  
1,800,000 EUR

FUNDING ROUND  
SERIES B

## SUPERCONNECTORS



IDEAL CONNECTION  
Pharma BD&L heads and top tier KOLs.

CRITICAL ASK  
Access to pharma companies that have a focus in neurodegeneration.

## INNOVATION AND GROWTH

**TECHNOLOGY:** We developo brain available and orally stable compounds that manage to disassembl neurotoxic oligomers, which are cause to various neurological disorders. Key to our approach is a completely novel mechanism of action.

TRL 7: to be achieved for PRI-002 in Alzheimer's disease after successful completion of Ph II.

Other pipeline programs at preclinical stage, thus TRL 5 and below.

**IP:** broad patent portfolio completely owned by Priavoid.

**STATUS:** Ongoing Phase II trial in Alzheimer's and successful transfer of concept to other drug targets in preclinical stages.

**NEXT MILESTONE:** by Q3/2026 demonstrate efficacy in Phase II Alzheimer's trial.

**VISION:** We are fighting some of the most devastating neurological diseases and our vision is to take the terror out of diseases such as Alzheimer's.



Dieter Willbold  
Co-Founder



Philipp Bürling  
CEO

# QUANTUM DIAMONDS

QD REVOLUTIONIZES SEMICONDUCTOR FAILURE ANALYSIS WITH QUANTUM SENSING, ENABLING ULTRA-PRECISE, NON-DESTRUCTIVE DEFECT DETECTION TO MAXIMIZE YIELD AND ACCELERATE TIME-TO-MARKET.

---

## COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
30

LOCATION  
Munich, Germany

WEBSITE  
[quantumdiamonds.de](http://quantumdiamonds.de)

## BUSINESS MODEL

QD sells quantum sensing devices and offers an analytics layer for advanced failure analysis and semiconductor quality control.

FUNDING DILUTIVE  
3,300,000 USD

FUNDING COMMITTED  
25,000,000 USD

FUNDING NON-DILUTIVE  
30,000,000 USD

FUNDING NEEDED  
10,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Semiconductor experts, Late Stage Deep Tech  
Investors, Policymakers, Politicians

### CRITICAL ASK

We seek support in building its political standing, branding, and network in Germany. With key policymakers and industry stakeholders we want to drive the adoption of quantum sensing technology in advanced semiconductor manufacturing.



## INNOVATION AND GROWTH

**TECHNOLOGY:** QD utilizes NV centers in synthetic diamonds for high-precision, non-destructive magnetic and electric field sensing. This enables fast, sub-micrometer resolution failure analysis and defect detection in advanced semiconductor circuits.

**TRL 9:** with a fully operational commercial demo tool, which is installed at Fraunhofer for commercial testing with semiconductor companies

**IP:** 13 total IP rights (6 patents)

**STATUS:** QuantumDiamonds has built the first commercially ready quantum sensing tool for failure analysis in advanced semiconductor manufacturing and assembled a world-class team of quantum physicists and engineers.

**NEXT MILESTONE:** Deliver the first devices overseas to Taiwan and the US.

**VISION:** QuantumDiamonds envisions becoming a leading player in failure analysis for advanced semiconductor manufacturing, driving the industry forward with quantum sensing technology.



Fleming Bruckmaier  
Co-Founder and CTO



Kevin Berghoff  
Co-Founder and CEO

# RADICAL DOT

TRANSFORMING PLASTIC WASTE  
FROM A GLOBAL PROBLEM INTO A  
VALUABLE RESOURCE.

---

## COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
6

WEBSITE  
radicaldot.com

LOCATION  
Munich, Germany

REVENUE  
156,000 EUR

## BUSINESS MODEL

Our business model is to commercialize our novel chemical recycling technology & process, initially generating revenue through R&D and proof-of-concept projects, then scaling via chemical sales and technology licensing.

FUNDING DILUTIVE  
2,645,000 EUR

FUNDRAISING  
Q2-3/2026

FUNDING ROUND  
SEED

FUNDING NEEDED  
10,000,000 EUR

FUNDING NON-DILUTIVE  
233,000 EUR

## SUPERCONNECTORS



### IDEAL CONNECTION

Knowledgeable and experienced EPC players specialised in chemical pilot plant facilities.

### CRITICAL ASK

Access to top tier chemical engineering talent and scale-up know-how (e.g., engineering, site selection, EPC partnership, pilot plant commissioning).



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our proprietary liquid-phase oxidation technology converts mixed plastic waste into cost-effective, low-emission chemical building blocks—without external energy input.

**TRL:** 4 kg-scale experiments in semi-continuous operation

**IP:** 1 pending, 1 making

**STATUS:** The technology has been successfully validated in the lab and is being scaled up for continuous kilogram-scale production.

**NEXT MILESTONE:** by Q2/2025: Continuous kg-scale pilot reactor system operational.

**PROOF OF CONCEPT:** 2 PoC with Greiner Innovations & CITEO, 1 LOI in the making, 2 PoC in pipeline.

**VISION:** Our vision is a circular economy where plastic waste unlocks a fossil-free chemical industry.



Alexandre Kremer  
Co-Founder



Andreas Wagner  
Co-Founder and CTO

[back to overview](#)

# REVERION

CO<sub>2</sub>-NEGATIVE, HIGH-EFFICIENCY POWER PLANTS WITH MODULAR, SCALABLE DESIGN FOR SUSTAINABLE ENERGY.

---

## COMPANY DETAILS

FOUNDED  
2022

EMPLOYEES  
140

LOCATION  
Eresing, Germany

WEBSITE  
reverion.de

## BUSINESS MODEL

Our business model focuses on manufacturing and selling standardized, containerized power plants. Additionally, we generate recurring revenue through maintenance contracts, priced at 4% of the selling price per year, ensuring long-term reliability and performance for our customers.

FUNDING DILUTIVE  
60,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING NEEDED  
50,000,000 EUR

FUNDING ROUND  
SERIES B

## SUPERCONNECTORS



### IDEAL CONNECTION

We are looking to connect with debt finance providers who specialize in clean energy, industrial scaling, or infrastructure financing.

### CRITICAL ASK

Non-Equity Funding, Debt Financing, Hydrogen Off-Take Agreements

## INNOVATION AND GROWTH

**TECHNOLOGY:** We develop reversible, CO<sub>2</sub>-negative power plants using patented technology. Our modular, scalable container units enable Plug & Play installation, seamlessly replacing existing engines. Designed for series production, they drive rapid market adoption and a sustainable future.

**STATUS:** Our pilot testing was successful, and we are now in the pre-series phase while scaling our production site for series production.

**NEXT MILESTONE:** First series Production

**PROOF OF CONCEPT:** 5 Power Plants

**TRL:** 8

**IP:** 3 awarded, 4 pending, more in making

**VISION:** We envision a world where energy production is not only highly efficient but also entirely sustainable. Our mission is to revolutionize the way energy is generated and utilized, driving the transition to a truly carbon-neutral future.



Stephan Herrmann  
Co-Founder and CEO



Felix Fischer  
Co-Founder and COO

# RULEMAPPING

MAKING LAW MACHINE-READABLE  
AND AI APPLICABLE IN DETERMINISTIC  
PROCESSES.

---

## COMPANY DETAILS

FOUNDED  
2002/2024

EMPLOYEES  
25

WEBSITE  
[rulemapping.com/en](http://rulemapping.com/en)

LOCATION  
Berlin, Germany

REVENUE  
> 5,000,000 EUR

## BUSINESS MODEL

We offer no-code automation, a digital legislation editor, and patent-pending Rule Based AI as SaaS solutions. Outperforming BPMN, our technology streamlines compliance and legal processes by transforming complex regulations into clear, editable rule maps. Revenue: licenses, training, partnerships.

FUNDING DILUTIVE  
12,000,000 EUR

FUNDING NON-DILUTIVE  
1,000,000 EUR

## SUPERCONNECTORS



### IDEAL CONNECTION

1.) Big Tech ERP, 2.) Global Consulting Firms/  
Public Sector Leads, 3.) Private Equity

### CRITICAL ASK

Access to high-level decision-makers in government and enterprises to accelerate adoption of automated legal processes and digital legislation solutions.

## INNOVATION AND GROWTH

**TECHNOLOGY:** A standardized notation for legal queries, combining rule-based systems with LLMs for automation in judiciary, public administration, and compliance.

**TRL:** 9 Automation software and rule-based AI fully operational in government and enterprise environments, enabling compliant and scalable automation of legal processes.

**IP:** Rule Based AI patent filed and pending

**STATUS:** Dozens of clients across the private sector, public administration, and

judiciary using our no-code automation software, legislation editor, and Rule Based AI.

**NEXT MILESTONE:** Q3/2025: Launch of Rule Based AI V2, hallucination-free AI technology for compliant and comprehensible legal assessments. Q4/2025: Launch of open-source digital legislation editor.

**PROOF OF CONCEPT:** BImSchV in Baden-Württemberg, judicial assistance system in Schleswig-Holstein

**VISION:** We enable functioning states by making bureaucracy efficient, transparent, and accessible. As the first and only solution, we make AI applicable for the compliant and comprehensible automation of complex legal assessments, and build an open source digital legislation ecosystem as public administration infrastructure — ensuring that laws serve people, foster trust, and strengthen democracy.



Ina Remmers  
Geschäftsführerin



Till Behnke  
CEO



Stephan Breidenbach  
Legal Tech Pionier

# SECUBLOX

DEFEAT DEEPPFAKES RIGHT AT THE  
SOURCE OF INCEPTION – EMBED  
IMMUTABLE TRUST SO WE CAN  
TRUST DIGITAL AGAIN.

---

## COMPANY DETAILS

FOUNDED  
2024

EMPLOYEES  
6

WEBSITE  
secublox.com

LOCATION  
Neu-Biberg, Germany

REVENUE  
210,000 EUR

## BUSINESS MODEL

Our business model is to supply a modular hardware-and-software tech stack on a tiered licensing plan for industrial and defense customers, with a one-time hardware purchase. License tiers scale by data classification levels and structured data throughput needs

FUNDING NEEDED  
2,000,000 EUR

FUNDRAISING  
Q4 2025

FUNDING NON-DILUTIVE  
670,000 EUR

FUNDING ROUND  
PRE-SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

government and defense contacts as well as  
public sector representatives.

### CRITICAL ASK

Access to capital and access to market.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology fuses cryptographic watermarking into secure hardware, adds immutable blockchain verification, and advanced AI detection, fortified by zero-knowledge proofs: All to ensure digital content is authenticated at inception for tamper-proof trust.

**TRL 4:** Technology is validated in the lab with secure data exchange of autonomous drone swarms and hardware in the loop. By end of Q4 2025 it will be validated in relevant NATO environment and thus reach TRL 5.

**STATUS:** Steering of autonomous drones and hardware in the loop was tested in the

lab. In Q3 2025 it will be validated through a NATO interoperability exercise with different nations. In Q4 2025 technology will be validated with the German Bundeswehr secure communication of image data from drone to land machines.

**NEXT MILESTONE:** by Q3 2025 as part of the NATO accelerator program testing in relevant environment.

**PROOF OF CONCEPT:** PoC with IABG with autonomous drone swarms and with Airbus for their Future Combat Air System integration, PoC with Bundeswehr through NATO planned for Q4 2025.

**VISION:** Our vision is to revolutionise digital trust by securing data at the point of inception. As deepfakes and digital manipulations continue to challenge our perceptions, secublox paves the way for a future where every data is inherently trustworthy - one where authenticity is never compromised.



Stephanie Wißmann  
Co-Founder



Dirk Stauder  
Co-Founder

# SEMRON

## 3D AI CHIPS FOR GEN AI EVERYWHERE, ANY DEVICE.

---

### COMPANY DETAILS

FOUNDED  
2020

EMPLOYEES  
19

LOCATION  
Dresden, Germany

WEBSITE  
semron.ai

### BUSINESS MODEL

We sell our AI chips as unpackaged dies to SoC vendors and as packaged solutions to consumer electronics OEMs, including interface IP and drivers for seamless integration. We do not license our core IP, ensuring a competitive edge and maintaining a high innovation potential as genuine venture case.

FUNDING DILUTIVE  
8,7000,000 EUR

FUNDING COMMITTED  
11,000,000 EUR

FUNDING NON-DILUTIVE  
3,500,000 EUR

FUNDING NEEDED  
55,000,000 EUR

FUNDRAISING  
STARTING Q4 2025

FUNDING ROUND  
SERIES A

### SUPERCONNECTORS



#### IDEAL CONNECTION

Decision-makers for foundry access (CMOS-compatible 3D CapRAM™ process) and product group owners for PoCs in audio consumer electronics.

#### CRITICAL ASK

Access to market (audio devices for 1st chip generation): PoC project

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology pioneers 3D monolithic growth for AI computing, inspired by the success of 3D memory. Growing compute layers on a single wafer improves compute density 100x while keeping the form factor and costs constant. Notably, our memcapacitive in-memory computing approach prevents overheating.

**TRL:** 6 CapRAM development is complete (process freeze for 2D CapRAM), and circuit components have been successfully tested, demonstrating the functionality and reliability of all subcomponents. This validation marks a critical step toward full system integration.

**IP:** Patents: 2 granted; 6 pending; 3 making  
**STATUS:** CapRAM was lab-validated four years ago and transferred to a high-volume foundry. With circuit components successfully validated, the next milestone is a fully integrated system for our Q3/25 evaluation kit. The 3D-scaled version is validated and now being transferred to leading tool manufacturers.

**NEXT MILESTONE:** Q2/25: on-device live translation demo; Q3/25: eval board 1st chip generation (2D)

**PROOF OF CONCEPT:** 1 POC with leading German defense company

**VISION:** Enhancing human capabilities to compete with machines—enabling real-time translation, intelligent digital assistance, and non-linear productivity scaling with always-on, truly on-device AI.



Aron Kirschen  
CEO



Kai-Uwe Demasius  
CTO

# SNIPR BIOME

RADICALLY DISRUPT AND IMPROVE  
TREATMENTS BRINGING CRISPR  
MEDICINES TO MILLIONS OF PEOPLE  
AT LOW COST.

---

## COMPANY DETAILS

FOUNDED  
2017

EMPLOYEES  
36

LOCATION  
Copenhagen, Denmark

WEBSITE  
sniprbiome.com

## BUSINESS MODEL

Our business model is to sell our CRISPR medicines directly into niche markets or to partner with large global pharma companies for wider commercial reach.

FUNDING DILUTIVE  
62,000,000 EUR

FUNDING COMMITTED  
30,000,000 EUR

FUNDING NON-DILUTIVE  
13,000,000 EUR

FUNDING NEEDED  
20,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING ROUND  
SERIES B, 2ND CLOSE

## SUPERCONNECTORS



### IDEAL CONNECTION

Investors (venture capital, family offices, foundations) interested in breakthrough CRISPR medicines.

### CRITICAL ASK

Access to venture capital for clinical proof-of-concept of new CRISPR medicine.

## INNOVATION AND GROWTH

**TECHNOLOGY:** First technological advancement: precise targeting of antibiotic resistant bacteria using CRISPR to solve the global antimicrobial crisis. Second: turning patient's guts into a medicinal factory using engineered bacteria as gut factories of therapeutics to treat immunological and metabolic disorders.

First CRISPR medicine: TRL 6 - currently under clinical evaluation for efficacy.

Second CRISPR medicine: TRL 5 - proof-of-concept in animals, ready for clinical validation.

IP: Early and broad IP on CRISPR: 60+ granted patents worldwide; 30+ granted patents in the US, 130+ pending patent applications.

**STATUS:** We are currently studying our first CRISPR medicine in vulnerable cancer patients at high risk of life-threatening infections. In parallel, advancing our deeper pipeline towards clinical testing in cardiometabolic and immunological disorders.

**NEXT MILESTONE:** First human study with novel Microbial-based preventive medicine for Obesity/Type-2 Diabetes completed by Q4/2026.

**PROOF OF CONCEPT:** Early striking clinical effect of first CRISPR medicine when used under emergency use IND treating a multidrug resistant infection in a kidney transplant patient with malakoplakia.

**VISION:** Our vision is to free the world from antibiotic resistant super bugs and treat immunological and metabolic disorders using CRISPR based medicines.



Jakob Krause Haaber  
VP, Head of Research



Eric van der Helm  
VP, Head of Business Development

# SPARK E-FUELS

NEXT-GEN SYNGAS PROCESS TO  
ENABLE LOWEST-COST E-FUELS  
DIRECTLY FROM RENEWABLES.

## COMPANY DETAILS

FOUNDED 2021	EMPLOYEES 8
LOCATION Berlin, Germany	WEBSITE sparkefuels.com

## BUSINESS MODEL

Spark develops and engineers load-flexible e-SAF production systems, including its disruptive syngas step. This entails the engineering of core equipment and selling the overall system as OEM to e-SAF projects. Revenue is generated through equipment sales, royalties and recurring services.

FUNDING DILUTIVE 2,300,000 EUR	FUNDING NON-DILUTIVE 300,000 EUR	FUNDING ROUND SEED
FUNDING NEEDED 7,000,000 EUR	FUNDRAISING Q2/Q3 2026	

## SUPERCONNECTORS



**IDEAL CONNECTION**  
project developers, energy utilities, refineries,  
and chemicals companies that are interested  
in partnering for the development of an e-fuel  
demo plant

**CRITICAL ASK**  
Access to potential project partners for the  
development of a demo-size e-fuel plant (e.g.,  
project developers, energy utilities, refineries)

## INNOVATION AND GROWTH

**TECHNOLOGY:** Spark's core tech is a disruptive syngas conversion process that can be coupled with fluctuating, but low-cost renewables. Unlike conventional processes, Spark's process is fully flexible, reaches very high CO<sub>2</sub>-to-CO conversions of >95%, and is at lower temperature—whilst still highly scalable.

**TRL: 4** Achieved very promising results (>98% CO<sub>2</sub> to CO conversion) for syngas process in lab-setup and smaller pilot

**IP: 2** pending

**STATUS:** Spark's novel syngas process and catalyst material show very promising results in the lab and is now being scaled to pilot-scale to be combined with a Fischer-Tropsch process.

**NEXT MILESTONE:** - Q1/2026 start of operation of syngas pilot plant; - Q2/2026 combination of flexible syngas process with flexible Fischer-Tropsch process

**PROOF OF CONCEPT:** Tech shown in lab setup and now scaled to pilot scale

**VISION:** Spark e-Fuels is pioneering the future of sustainable aviation fuel production. With its cost-effective, demand-responsive e-fuel technology, powered by renewable energy, Spark enables net-zero aviation and broader industrial decarbonization.



Julia Bauer  
Co-Founder



Mathias Bösl  
Co-Founder



Arno Zimmermann  
Co-Founder and CTO

# STANHOPE AI

BRINGING A NEW AI TO THE PHYSICAL  
WORLD.

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
9

WEBSITE  
stanhopeai.com

LOCATION  
London, UK

REVENUE  
600,000 GBP

## BUSINESS MODEL

Our business model is to sell full autonomy solutions for Defence UxVs and Industrial UGVs. Later we intend to partner with OEMs and offer our AI in a software license and SaaS model.

FUNDING DILUTIVE  
2,300,000 GBP

FUNDING NON-DILUTIVE  
200,000 GBP

FUNDING ROUND  
SEED

FUNDING NEEDED  
5,000,000 GBP

FUNDRAISING  
Q2 2025

## SUPERCONNECTORS



IDEAL CONNECTION  
Defence & Industrial Robotics Leaders

CRITICAL ASK  
Access to Capital



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology uses Active Inference to build World Models for AI, built like a human brain. We have completed real world demos to TRL Level 6 in UAVs and UxVs. We are building out a foundational brain for all IRL robots by addressing revenue generating verticals with large TAMs.

**TRL 6:** demonstrated autonomous control and cognitive decision making in a relevant environment.

**IP:** Copyright Software

**STATUS:** The technology is validated in the field and being refined for OEM platforms

**NEXT MILESTONE:** AI World Model deployed on UAV and UGV platforms

**PROOF OF CONCEPT:** PoC with US DoD & UK MoD

**VISION:** Our vision is that embodied systems that lag behind digital AI will show the general, all purpose intelligence for in-the-world AI applications. Active Inference solves size & power problems of ML systems and catapults intelligence on-board.



Rosaly Moran  
CEO



Kevin Crain  
Growth Hacker

# TECHIFAB

## NEUROMORPHIC COMPUTING BEYOND BRAIN LEVEL EFFICIENCY.

### COMPANY DETAILS


FOUNDED 2021	EMPLOYEES 27	WEBSITE techifab.com
LOCATION Dresden, Germany	REVENUE 1,000,000 EUR	

### BUSINESS MODEL

TechiFab's TiF Technology Platform is a groundbreaking computing paradigm—faster, energy-efficient, and compact—designed to power the AI of the future. By licensing our IP to leading IDMs and design houses, we aim to make this technology globally accessible.

FUNDING DILUTIVE 2,400,000 EUR	FUNDING COMMITTED 20,000,000 EUR	FUNDING NON-DILUTIVE 4,600,000 EUR
FUNDING NEEDED 50,000,000 EUR	FUNDRAISING Q3/2025	FUNDING ROUND SERIES A

### SUPERCONNECTORS

	IDEAL CONNECTION IDM's, Foundries and Chip designers	CRITICAL ASK Access to capital and market
--	---	--

## INNOVATION AND GROWTH

TECHNOLOGY: TiF Platform Technology,  
a complete new semiconductor platform

and products for proven breakthrough  
base technology

TRL 3-4

NEXT MILESTONE: Q3/2025 production of  
the first Transistor in TiF Technology

IP: 24 patents, 16 awarded, 5 pending

PROOF OF CONCEPT: Under NDA but 5  
key players

STATUS: Developing industrial  
manufacturing processes, applications

**VISION: The next evolutionairy step in  
Computing Technology**



Guy Vroemen  
CEO



Heidemarie Krüger  
CTO

# TILIBIT

RAPID AND CERTAIN DIAGNOSES, AT  
10-FOLD LOWER COSTS, THROUGH  
HIGH-MULTIPLEX POINT-OF-CARE  
TESTING.

---

## COMPANY DETAILS

FOUNDED  
2012

EMPLOYEES  
33

WEBSITE  
tilibit.com

LOCATION  
Munich, Germany

REVENUE  
3,500,000 EUR

## BUSINESS MODEL

B2B sales of high-margin consumables with value-based pricing and significant lock-in effects.

FUNDING NEEDED  
40,000,000 EUR

FUNDRAISING  
Q3/2025

FUNDING NON-DILUTIVE  
20,000,000 EUR

FUNDING ROUND  
SERIES A

## SUPERCONNECTORS



### IDEAL CONNECTION

Investors specifically interested in physical products that create new markets in the health and life sciences area

### CRITICAL ASK

We are looking for investors specifically interested in physical products that create new markets in the health and life sciences area

## INNOVATION AND GROWTH

**TECHNOLOGY:** Programmable, self-assembling nanostructures bridge the gap between current generation tools and the molecular scale. This enables next-generation molecular sensors that can be produced at scale at 100-fold lower costs while simultaneously improving sensitivity and multiplexing.

R&D-targeted product: TRL 7/  
Ultra-high-throughput sequencing  
consumables: TRL 5 /POC  
diagnostic consumable: TRL 2

IP: 2 granted, 4 pending, 2 making

**STATUS:** Market entry with simple functionality product variants in 2025, in various stages of collaborations with industry partners for advanced product development.

**NEXT MILESTONE:** Q2/2025 Nanostructure integration into chip

**PROOF OF CONCEPT:** At various stages of collaboration with 4 industry partners (under NDA)

**VISION:** Unlocking the molecular scale



Jean-Philippe Sobczak  
CEO

[back to overview](#)

# TQ THERAPEUTICS

WE SAVE PATIENTS' LIVES BY MAKING  
LIFE-PRESERVING THERAPIES  
ACCESSIBLE TO EVERYONE.

---

## COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
9

LOCATION  
Munich, Germany

WEBSITE  
tqtherapeutics.com

## BUSINESS MODEL

Our business model is the commercialization of cell therapies with the aim of reducing costs and complexity. In addition, we will be a partner for companies developing their own ultra-short processes based on TQx cutting-edge technology.

FUNDING DILUTIVE  
3,200,000 EUR

FUNDING COMMITTED  
4,000,000 EUR

FUNDING NON-DILUTIVE  
700,000 EUR

FUNDING NEEDED  
7,000,000 EUR

FUNDRAISING  
Q4/2025

FUNDING ROUND  
SEED

## SUPERCONNECTORS



### IDEAL CONNECTION

An ideal connection for TQx would be a large pharmaceutical company that integrates the TQx platform into its cell therapy process development efforts. This synergy should accelerate innovation and ensure precise, effective treatments and improved patient outcomes through shared expertise.

### CRITICAL ASK

We are seeking for a strategic partnership with a major pharmaceutical company to enhance our impact and market visibility. Together, we can amplify our efforts to bring the innovative TQx process to those who need it, ultimately saving lives and improving global healthcare outcomes.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our key technology is based on our proprietary cell selection system that enables an ultra-fast and highly selective T cell enrichment and thereby allowing us for an automated and scalable extracorporeal targeted gene therapy process within hours.

**STATUS:** The TQx cell generation process technology has been validated on a laboratory scale with a PoC study and is currently being adapted for clinical applications. Our proprietary cell selection column is transferred for GMP manufacturing.

**TRL:** Technology available in non-GMP status

**NEXT MILESTONE:** by Q3/2025 - „Positive regulatory feedback on TQx process“

**IP:** 3 pending

**PROOF OF CONCEPT:** One PoC with Pantherna Therapeutics GmbH

**VISION:** Cell therapies are promising therapies, but face major bottlenecks that prevent their broad applicability. We revolutionize CGT and help change the patient's lives by making autologous cell therapies successful and embrace their full treatment potential in diseases that would never be treated.



Christian Eckert  
Founder and CEO



Sabine Radisch  
Co-Founder and CTO

# TRANSMUTEX

TURNING NUCLEAR WASTE INTO  
ENERGY, CANCER MEDICATION AND  
VALUABLE RAW MATERIALS.

---

## COMPANY DETAILS

FOUNDED  
2019

EMPLOYEES  
50

LOCATION  
Geneva, Switzerland

WEBSITE  
transmutex.com

## BUSINESS MODEL

Our business model is to sell the engineering design of our unique transmutation plant to operators/governments who sit on a stockpile of nuclear waste.

FUNDING DILUTIVE  
40,000,000 CHF

FUNDING COMMITTED  
15,000,000 EUR

FUNDING NON-DILUTIVE  
4,500,000 USD

FUNDING NEEDED  
30,000,000 EUR

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SERIES B



### IDEAL CONNECTION

Impact investors with a long-range vision.

### CRITICAL ASK

We are looking for partners who have the patience and the pockets this unusual project requires.



## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology is a plant design consisting of a first part separating nuclear waste into valuable raw materials, medical radioisotopes and a remainder of waste that the second part will transmute to energy and reduce its radioactivity from 1M to 1K years.

**TRL 6:** all components at TRL 9, but need to be demonstrated in combination

**IP:** ca. 10 patents awarded and 10 pending

**STATUS:** Various components are being tested and the conceptual design report written over the next 18 months.

**NEXT MILESTONE:** Start testing at Los Alamos National Laboratory in Q3/2025

**PROOF OF CONCEPT:** We aim to build a FOAK in Germany (general PoC was accomplished years ago at CERN, PSI and Argonne NatLab)

**VISION:** Our vision is that nuclear waste will become an asset for mankind rather than stay a liability for the next 10,000 generations.



Franklin Servan-Schreiber  
Co-Founder and CEO



Donovan Maire  
CTO

# ULTRABRIGHT BIOTECH

MAKING THE INVISIBLE VISIBLE.

---

## COMPANY DETAILS

FOUNDED  
2025

EMPLOYEES  
5

LOCATION  
Hallbergmoos by Munich,  
Germany

## BUSINESS MODEL

Ultrabright Biotech operates a B2B model, providing ultra-beacon technology to diagnostics companies and research institutions. By integrating seamlessly with existing platforms, we enable partners to enhance sensitivity, accelerate innovation, and expand their diagnostic capabilities across diverse applications.

FUNDING COMMITTED  
2,500,000 EUR

FUNDING NON-DILUTIVE  
SPRIND: 1.000.000 EUR

FUNDING ROUND  
SEED ROUND

FUNDING NEEDED  
5,000,000 EUR

FUNDRAISING  
Q2/2025

## SUPERCONNECTORS



**IDEAL CONNECTION**  
An introduction to (former) decision makers in a big diagnostic company to identify a potential fit - ideally Roche, Abbot or Siemens.

**CRITICAL ASK**  
Looking for corporate venture firms in the diagnostics space.

# INNOVATION AND GROWTH

**TECHNOLOGY:** Ultrabright Biotech harnesses cutting-edge DNA nanotechnology to create ultra-beacons—revolutionary nanostructures that decouple binding from signal generation. This versatile platform seamlessly integrates with state-of-the-art diagnostic instruments, amplifying their capabilities by orders of magnitude for unparalleled sensitivity.

**TRL:** 5 Laboratory validation and transition to relevant environments.

**IP:** 2 patents filed, both are pending

**STATUS:** Founded in 02/2025, 5 employees, Finished several successful customer projects with Dx majors

**NEXT MILESTONE:** We want to further de-risk the technology, finish PoC in different applications, and thus enter into further customer cooperations.

**PROOF OF CONCEPT:** Finished successful customer projects with diagnostic majors

**VISION:** Our vision is to make the invisible visible—unlocking unprecedented detection sensitivity to unveil the earliest signs of disease. By illuminating what was once undetectable, we empower groundbreaking interventions when they matter most.



Klaus Wagebauer  
Founder and CEO



Jonas Funke  
Founder



Benjamin Kick  
Founder

[back to overview](#)

# UNBOUND POTENTIAL

## MAKE RENEWABLE ENERGY POWER THE PLANET 24/7.

---

### COMPANY DETAILS

FOUNDED  
2023

EMPLOYEES  
18

LOCATION  
Thalwil, Switzerland

WEBSITE  
[unbound-potential.com](https://unbound-potential.com)

### BUSINESS MODEL

Our business model is to sell turnkey battery energy storage systems. While all the components are produced and integrated by contract manufacturers, our field engineers are taking care of quality control and comissioning, before handing over to the customer.

FUNDING COMMITTED  
5,000,000 CHF

FUNDING NON-DILUTIVE  
8,000,000 EUR

FUNDING NEEDED  
8,000,000 CHF

FUNDRAISING  
Q2/2025

FUNDING ROUND  
SEED ROUND

### SUPERCONNECTORS



#### IDEAL CONNECTION

Contact to leading renewable asset operators and project developers.

#### CRITICAL ASK

Access to capital, access to strategic manufacturing partners, acces to strategic implementation partners.  
Key target: customers.

## INNOVATION AND GROWTH

**TECHNOLOGY:** Our technology is a new membrane-less flow battery, based on a radically new design approach removing costly membranes in the cell stacks and using immiscible water-based liquids. This allows a cheaper, safer and more efficient flow battery.

**TRL 5:** Testing of cell stacks in industrial battery test stand.

**IP:** 1 awarded, 1 making

**STATUS:** The technology is validated in an industrial test environment. Currently tech KPIs are being optimized in preparation of a PoC project.

**NEXT MILESTONE:** By Q4/2025 - Design freeze for PoC installation with pilot partner.

**PROOF OF CONCEPT:** planned for 2026

**VISION:** Our vision is to enable the development of a resilient electrified society, independent of fossil fuels and critical raw materials.



Anetta Plataek-Mielczarek  
Co-Founder



David Taylor  
CEO



Emilio Dal Re  
Co-Founder



Pier Giuseppe Rivano  
Co-Founder

[back to overview](#)

# BIOTX.AI

CAUSAL MAPPING OF THE GENOME:  
UNVEILING THE GENES THAT CAUSE  
OR INFLUENCE BIOLOGICAL EFFECTS,  
TRAITS, OR DISEASES.

---

## COMPANY DETAILS

FOUNDED  
2017

EMPLOYEES  
12

WEBSITE  
biotx.ai

LOCATION  
Potsdam, Germany

REVENUE  
1,000,000 EUR

## BUSINESS MODEL

Through causal mapping of the genome, we elucidate the underlying biological mechanisms of diseases and enable robust prediction of clinical trial outcomes. Since launching our technology in late 2022, biotx.ai has been developing its own drug candidates while also partnering with biotech and pharmaceutical companies to optimize clinical development - receiving upfront payments, milestone-based compensation, and royalty agreements in return.

FUNDING DILUTIVE  
2,000,000 EUR

FUNDING NON-DILUTIVE  
1,500,000 EUR

FUNDING ROUND  
SERIES A

FUNDRAISING  
Q4/2025

## SUPERCONNECTORS



### IDEAL CONNECTION

Pharmaceutical companies and biotechs, looking for risk-shared co-developments enabled by our predictive tool based on the causally mapped genome.

### CRITICAL ASK

Pharma / biotech incubator / VCs partnerships.

## INNOVATION AND GROWTH

**TECHNOLOGY:** By curating a comprehensive catalog based on 9,539 genome-wide association study (GWAS) datasets including >22M cases across >3K diseases, biotx.ai tested all 23,280 genes and more than >1M Omics markers in >60 tissues for each disease using Mendelian randomization (MR). The platform leverages advanced machine learning to identify clusters, pinpointing the essential causal relationships of drug targets. This process connects drug targets directly to disease biology, uncovering novel candidates with verified causal links to various health conditions.

**STATUS:** Our causal inference platform is being used and challenged by dozens of biotech companies since its launch in late 2022.

**NEXT MILESTONE:** Engaging in risk-shared co-development partnerships with pharmaceutical companies.

**PROOF OF CONCEPT:** EUR >2M revenue since 2023 through collaborations with dozens of biotechs and pharmaceutical companies helping them optimize clinical development and secure crucial funding.

TRL 7

**VISION:** Our vision is to disrupt the high-risk biotech business model through a more predictable, data-driven approach. Through causal mapping of the genome, we elucidate disease biology and enable robust prediction of clinical trial success — paving the way for a new era in therapeutics.



Marco Schmidt  
Co-Founder





## IMPRESSUM

Booklet zum Event ‚VENTURE SPRIND‘

Veröffentlicht am: 08. April 2025, Leipzig (Deutschland)

## VERFASSTER:

SPRIND GmbH

Lagerhofstr. 4

04103 Leipzig

INFO@SPRIND.ORG

## Unsere Geschäftsführung:

Berit Dannenberg

Rafael Laguna de la Vera

## Vorsitzender des Aufsichtsrats:

Dr.-Ing. E. h. Peter Leibinger

## Handelsregister:

Amtsgericht Leipzig (HRB 36977)

Umsatzsteuer-Identifikationsnummer nach § 27a

Umsatzsteuergesetz DE328253854

## INHALTE DER TEAM-SEITEN:

Die dargestellten Unternehmen tragen die alleinige Verantwortung für den Inhalt der Team-Seiten.

## KONZEPT UND DESIGN:

SPRIND GmbH

## BILDNACHWEIS:

Die Personenbilder und Teamlogos in diesem Booklet wurden von den entsprechenden Unternehmen zur Nutzung im Rahmen des Events ‚VENTURE SPRIND‘ am 08. April 2025 bereitgestellt. Alle anderen Abbildungen und Fotos sind Eigentum der SPRIND GmbH.

[back to overview](#)





A HOME FOR PEOPLE  
WITH RADICAL NEW IDEAS

**SPRIN-D**